0001493152-23-040402.txt : 20231113 0001493152-23-040402.hdr.sgml : 20231113 20231113124118 ACCESSION NUMBER: 0001493152-23-040402 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BLUE BIOFUELS, INC. CENTRAL INDEX KEY: 0001549145 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 454944960 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54942 FILM NUMBER: 231397105 BUSINESS ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 BUSINESS PHONE: (888)607-3555 MAIL ADDRESS: STREET 1: 3710 BUCKEYE ST STREET 2: SUITE 120 CITY: PALM BEACH GARDENS STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: ALLIANCE BIOENERGY PLUS, INC. DATE OF NAME CHANGE: 20141204 FORMER COMPANY: FORMER CONFORMED NAME: Alliance Media Group Holdings, Inc. DATE OF NAME CHANGE: 20120504 10-Q 1 form10-q.htm
false --12-31 Q3 false 0001549145 0001549145 2023-01-01 2023-09-30 0001549145 2023-11-10 0001549145 2023-09-30 0001549145 2022-12-31 0001549145 us-gaap:NonrelatedPartyMember 2023-09-30 0001549145 us-gaap:NonrelatedPartyMember 2022-12-31 0001549145 us-gaap:RelatedPartyMember 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-12-31 0001549145 2023-07-01 2023-09-30 0001549145 2022-07-01 2022-09-30 0001549145 2022-01-01 2022-09-30 0001549145 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001549145 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001549145 us-gaap:CommonStockMember 2022-12-31 0001549145 us-gaap:PreferredStockMember 2022-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001549145 us-gaap:RetainedEarningsMember 2022-12-31 0001549145 us-gaap:CommonStockMember 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-03-31 0001549145 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-06-30 0001549145 2023-06-30 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 2022-06-30 0001549145 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001549145 2023-01-01 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001549145 2023-04-01 2023-06-30 0001549145 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001549145 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001549145 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001549145 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001549145 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001549145 us-gaap:CommonStockMember 2023-09-30 0001549145 us-gaap:PreferredStockMember 2023-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001549145 us-gaap:RetainedEarningsMember 2023-09-30 0001549145 us-gaap:CommonStockMember 2022-09-30 0001549145 us-gaap:PreferredStockMember 2022-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001549145 us-gaap:RetainedEarningsMember 2022-09-30 0001549145 2022-09-30 0001549145 us-gaap:CostOfGoodsProductLineMember us-gaap:ProductConcentrationRiskMember BIOF:VertimassTechnologyMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 srt:MinimumMember 2023-09-30 0001549145 srt:MaximumMember 2023-09-30 0001549145 us-gaap:BuildingImprovementsMember 2023-09-30 0001549145 us-gaap:BuildingImprovementsMember 2022-12-31 0001549145 us-gaap:MachineryAndEquipmentMember 2023-09-30 0001549145 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001549145 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001549145 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001549145 us-gaap:ComputerEquipmentMember 2023-09-30 0001549145 us-gaap:ComputerEquipmentMember 2022-12-31 0001549145 BIOF:PilotPlantMember 2023-01-01 2023-09-30 0001549145 BIOF:MachineryMember 2023-01-01 2023-09-30 0001549145 BIOF:MachineryMember 2023-09-30 0001549145 BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-08-10 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-08-10 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-08-09 2023-08-10 0001549145 us-gaap:WarrantMember BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-08-09 2023-08-10 0001549145 BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-07-31 0001549145 BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-07-31 0001549145 us-gaap:CommonStockMember BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-07-31 0001549145 us-gaap:CommonStockMember BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-07-01 2023-07-31 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-06-01 2023-06-30 0001549145 us-gaap:WarrantMember BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-06-01 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtTwoMember 2023-06-30 0001549145 us-gaap:CommonStockMember BIOF:ChrisKneppersMember BIOF:ConvertibleDebtTwoMember 2023-06-30 0001549145 us-gaap:CommonStockMember BIOF:ConvertibleDebtTwoMember BIOF:ChrisKneppersMember 2023-06-01 2023-06-30 0001549145 BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-04-30 0001549145 BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-04-01 2023-04-30 0001549145 us-gaap:CommonStockMember BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-04-30 0001549145 us-gaap:CommonStockMember BIOF:EdmundBurkeMember us-gaap:ConvertibleDebtMember 2023-04-01 2023-04-30 0001549145 BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember 2023-01-31 0001549145 us-gaap:CommonStockMember BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember 2023-01-31 0001549145 us-gaap:CommonStockMember BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember 2023-01-01 2023-01-31 0001549145 us-gaap:RelatedPartyMember BIOF:AMGEnergyGroupMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember us-gaap:RelatedPartyMember 2016-07-01 2016-07-31 0001549145 BIOF:MarkKochMember BIOF:AMGEnergyGroupMember 2016-07-31 0001549145 BIOF:AnimatedFamilyFilmsMember BIOF:AMGEnergyGroupMember 2016-07-31 0001549145 BIOF:StevenDunkleCTWCWellingtonAssetHoldingsMember BIOF:AMGEnergyGroupMember 2016-07-31 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember 2018-02-28 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember 2018-02-28 2018-02-28 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-02-28 2018-02-28 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-05-15 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-05-15 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-06-30 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-05-15 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-05-15 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-06-30 0001549145 BIOF:AMGEnergyGroupMember us-gaap:NotesPayableOtherPayablesMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember us-gaap:NotesPayableOtherPayablesMember 2016-07-01 2016-07-31 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2017-11-30 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2017-11-01 2017-11-30 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-05-01 2018-05-31 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-02-28 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-02-01 2018-02-28 0001549145 2019-03-26 0001549145 2019-03-27 0001549145 us-gaap:RelatedPartyMember 2023-09-30 0001549145 BIOF:OtherRelatedPartyMember 2023-09-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2023-01-01 2023-09-30 0001549145 2020-09-01 0001549145 2020-09-01 2020-09-01 0001549145 us-gaap:SubsequentEventMember 2023-10-01 2023-11-07 0001549145 us-gaap:SubsequentEventMember us-gaap:RelatedPartyMember 2023-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarter ended September 30, 2023

 

Commission File Number: 000-54942

 

BLUE BIOFUELS, INC.

(Exact name of small Business Issuer as specified in its charter)

 

Nevada   45-4944960
(State or other jurisdiction   (IRS Employer
of incorporation or organization)   Identification No.)

 

3710 Buckeye Street, Suite 120    
Palm Beach Gardens, FL   33410
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (888) 607-3555

 

n/a

Former name or former address if changed since last report

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Securities registered pursuant to Section 12(g) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock par value $0.001   BIOF   OTCQB

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒.

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒ Emerging Growth Company ☐
    Smaller reporting company ☒  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

The aggregate market value of the voting stock held by non-affiliates of the registrant as of the last business day of the registrant’s most recently completed second fiscal quarter was $29,189,366.

 

State the number of shares outstanding of the registrant’s $.001 par value common stock as of the close of business on the latest practicable date (November 13, 2023): 302,750,963.

 

 

 

 
 

 

TABLE OF CONTENTS

 

    Page
  PART I—FINANCIAL INFORMATION  
     
ITEM 1. Consolidated Financial Statements (unaudited)  
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 23
ITEM 4. Controls and Procedures 23
     
  PART II—OTHER INFORMATION  
     
ITEM 1. Legal Proceedings 24
ITEM 1A. Risk Factors 24
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 24
ITEM 3. Defaults Upon Senior Securities 25
ITEM 4. Mine Safety Disclosures 25
ITEM 5. Other Information 25
ITEM 6. Exhibits 25
  Signatures 26

 

2

 

 

PART I – FINANCIAL INFORMATION

 

TABLE OF CONTENTS

 

Index to Financial Statements   Page
Condensed Consolidated Balance Sheets as of September 30, 2023 (unaudited) and December 31, 2022   4
     
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2023 and 2022 (unaudited)   5
     
Condensed Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2023 and 2022 (unaudited)   6
     
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2023 and 2022 (unaudited)   7
     
Notes to Condensed Consolidated Financial Statements (unaudited)   8

 

3

 

 

Blue Biofuels, Inc.

Financial Statements

Period Ended September 30, 2023

 

UNAUDITED FINANCIAL STATEMENTS

OF

BLUE BIOFUELS, INC.

 

Blue Biofuels, Inc.

CONDENSED BALANCE SHEETS

(unaudited)

 

   September 30,
2023		   December 31,
2022		 
ASSETS          
Current assets          
Cash and cash equivalents  $84,663   $211,901 
Grants receivable  $130,835      
Prepaid expenses   38,209    43,119 
TOTAL CURRENT ASSETS  $253,707   $255,020 
Long-term assets          
Property and equipment, net of accumulated depreciation and amortization of $214,125 and $127,178 at September 30, 2023 and December 31,2022, respectively   612,258    420,115 
Security deposits   30,276    30,276 
Right of Use Assets, net of accumulated amortization   105,418    178,399 
Patents   247,854    222,109 
TOTAL LONG-TERM ASSETS  $995,806   $850,899 
TOTAL ASSETS  $1,249,513   $1,105,919 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
Current liabilities          
Accounts payable  $698   $37,135 
Accounts payable - Related Party   72,670   $72,670 
Deferred wages and director’s fees - Related party   674,594   $307,606 
Lease Liability - Current   101,905   $95,172 
Chapter 11 Settlement   -    50,000 
Convertible Notes Payable — Related Party   350,000    - 
Interest Payable - Related Party   120,124    76,138 
TOTAL CURRENT LIABILITIES  $1,319,991   $638,721 
Long term liabilities          
Right of Use Lease Liability, net of current portion   8,793    85,983 
Notes Payable — Related Party   2,796,562    2,521,562 
Notes Payable — Other   216,570    216,570 
TOTAL LONG TERM LIABILITIES  $3,021,925   $2,824,115 
TOTAL LIABILITIES  $4,341,916   $3,462,836 
           
STOCKHOLDERS’ EQUITY (DEFICIT)          
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding   -    - 
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 302,750,963 issued and outstanding at September 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022.   302,751    289,942 
Additional paid-in capital   51,936,716    50,134,727 
Accumulated deficit   (55,331,869)   (52,781,586)
Total stockholders’ equity (deficit)  $(3,092,403)  $(2,356,917)
TOTAL EQUITY (DEFICIT)  $(3,092,403)  $(2,356,917)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $1,249,513   $1,105,919 

 

4

 

 

Blue Biofuels, Inc

CONSOLIDATED STATEMENT OF OPERATIONS

(unaudited)

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   30-Sep   30-Sep 
   2023   2022   2023   2022 
Revenues  $-   $-   $-   $- 
Operating expense:                    
General and administrative   219,160    178,512    943,953    1,223,083 
Research & Development   293,674    404,157    1,741,318    2,070,789 
Loss on disposal of assets   -    -    369    40,099 
Total operating expenses   512,834    582,669    2,685,640    3,333,971 
                     
Loss from operations:   (512,834)   (582,669)   (2,685,640)   (3,333,971)
                     
Other (income) expense:                    
Grants received   (206,500)   -    (206,500)   - 
Interest expense - related party   23,218    6,711    63,712    20,135 
Interest expense - other   2,443    29,313    7,431    30,934 
Total other (income) expense   (180,839)   36,024    (135,357)   51,069 
                     
Income (Loss) before provisions for income taxes  $(331,995)  $(618,693)  $(2,550,283)  $(3,385,040)
Provisions for income taxes   -    -           
Net Income / (Loss):  $(331,995)  $(618,693)  $(2,550,283)  $(3,385,040)
                     
Net income (loss) per share  $(0.001)  $(0.002)  $(0.008)  $(0.012)
                     
Basic and Diluted Earnings per share  $(0.001)  $(0.002)  $(0.008)  $(0.012)
                     
Weighted average common shares outstanding                    
Basic & Fully Diluted   302,750,963    277,416,282    302,750,963    277,416,282 

 

5

 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

 

   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
   Common Stock   Preferred Stock   Additional Paid-in   Accumulated   Total Stockholder’s 
   Shares   Amount   Shares   Amt   Capital   Deficit   (Deficit) 
Balance as of December 31, 2022   289,941,623   $289,942          -    -   $50,134,727   $(52,781,586)  $(2,356,917)
Issuance of common stock for services   140,000   $140    -        -   $23,860    -   $24,000 
Issuance of common stock and warrants for cash through PPM   3,884,998   $3,885    -    -   $578,865    -   $582,750 
Warrants exercised   5,450,148   $5,450    -    -   $66,800    -   $72,250 
Vesting of 2,385,000 options under the employee, director plan             -    -   $391,297    -   $391,297 
Net Income (Loss)                            (1,064,090)  $(1,064,090)
Balance as of March 31, 2023   299,416,769   $299,417    -    -   $51,195,549   $(53,845,676)  $(2,350,710)
Issuance of common stock for services   34,194    34    -    -    5,266    -    5,300 
Vesting of 2,000,000 options under the employee, director plan             -    -    245,732    -    245,732 
Issuance of common stock and warrants for cash through PPM   633,334    633    -    -    94,389    -    95,022 
Issuance of 314,000 warrants for services             -    -    42,634    -    42,634 
Warrants exercised   500,000    500    -    -    24,500    -    25,000 
Net Income (Loss)                            (1,154,199)   (1,154,199)
Balance as of June 30, 2023   300,584,297   $300,584    -    -   $51,608,069   $(54,999,875)  $(3,091,221)
Issuance of 50,000 warrants for services                  -    5,813         5,813 
Issuance of common stock and warrants for cash through PPM   2,166,666   $2,167             $322,833         325,000 
Net Income (Loss)                            (331,995)  $(331,995)
Balance as of September 30, 2023   302,750,963    302,751         -   $51,936,715   $(55,331,870)  $(3,092,403)
                                    
Balance as of December 31, 2021   274,003,883   $274,004    -    -   $47,151,353   $(48,821,403)  $(1,396,046)
Issuance of common stock for services   447,781   $448    -    -   $70,852    -   $71,300 
Employee stock options exercised   150,000   $150    -    -   $7,350    -   $7,500 
Vesting of 10,560,000 options under the employee, director plan             -    -   $1,316,277    -   $1,316,277 
Net Income (Loss)                            (2,040,957)  $(2,040,957)
Balance as of March 31, 2022   274,601,664   $274,602    -    -   $48,545,832   $(50,862,360)  $(2,041,926)
Issuance of common stock for services   78,600   $79    -    -   $16,071    -   $16,150 
Employee stock options exercised   200,000    200    -    -    8,200    -    8,400 
Vesting of 800,000 options under the employee, director plan             -    -    99,106    -    99,106 
                                    
Issuance of common stock and warrants for cash through PPM   4,499,999    4,500    -    -    670,500    -    675,000 
Net Income (Loss)                            (725,390)   (725,390)
Balance as of June 30, 2022   279,380,263   $279,380    -    -   $49,339,710   $(51,587,750)  $(1,968,660)
                                    
Issuance of common stock for services   168,842   $169    -    -   $28,981    -   $29,150 
Vesting of 825,000 options under the employee, director plan        -    -    -    110,922    -    110,922 
Issuance of 37,333 warrants for services             -    -    5,317    -    5,317 
Issuance of common stock and warrants for cash through PPM   2,266,665    2,267    -    -    337,733    -    340,000 
Net Income (Loss)                            (618,693)  $(618,693)
Balance as of September 30, 2022   281,815,770   $281,817    -    -   $49,822,662   $(52,206,443)  $(2,101,964)

 

6

 

 

Blue Biofuels, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   For the Nine Months Ended   For the Nine Months Ended 
   30-Sep-23   30-Sep-22 
Cash flows from operating activities          
Net Income (Loss)  $(2,550,283)  $(3,385,040)
Reconciliation of net loss to net cash used in operating activities          
Depreciation and amortization   89,526    102,711 
Stock based compensation for services   29,300    116,600 
Net Issuance of options and warrants for services   685,474    1,531,622 
Loss on Disposal of assets   369    40,099 
Changes in operating assets and liabilities          
Prepaid expenses   4,910    (41,729)
Grants receivable   (130,835)     
Accrued interest - related party   43,986    20,135 
Accounts payable and accrued liabilities   330,551    62,996 
Right of use lease   2,525    (33,647)
Net cash used in operating activities   (1,494,477)   (1,586,253)
           
Cash flows from investing activities          
Net Purchase of property and equipment   (282,038)   (61,800)
Patent Costs   (25,744)   (42,501)
Net cash from (used in) investing activities   (307,782)   (104,301)
           
Cash flows from financing activities          
Proceeds from exercise of warrants and options   97,250    15,900 
Net Proceeds from the issuance of Convertible Notes   625,000      
Net proceeds from issuance of common stock   1,002,772    1,015,000 
Payment of Debt   (50,000)     
Net cash provided by financing activities   1,675,022    1,030,900 
           
Net increase (decrease) in cash and cash equivalents   (127,237)   (659,653)
           
Cash and cash equivalent at beginning of the period   211,901    1,164,664 
Cash and cash equivalent at end of the period  $84,663   $505,010 
           
Supplemental disclosure of cash flow information          
Cash paid during the period for          
Interest  $-   $- 
Taxes  $-   $- 
           
Supplemental schedule of non-cash activities          
Issuance of warrants for services  $48,447   $5,317 
Issuance of common stock for services  $29,300   $116,600 
Cashless conversion of warrants/options  $-   $- 
Conversion of convertible debenture to common stock  $-   $- 

 

7

 

 

Blue Biofuels, Inc.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new reactor technology with a higher yield and a continuous throughput in the Cellulose-to-Sugar process, or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with the technical staff of the Company. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in Japan and El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

The Company believes a significant difference between CTS cellulosic ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. The Company believes that it can optimize the pre and post processing elements at this pilot scale plant to finalize design and operational parameters to provide operating cost estimates of a full-scale commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

8

 

 

In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline. The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

Plan of Operation

 

The total process from cellulosic feedstock to SAF consists basically of three steps:

 

  1) Conversion from feedstock to fermentable cellulosic sugars (CTS)
  2) Ferment the cellulosic sugars into cellulosic ethanol.
  3) Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed.

 

Given the fact that the Vertimass technology is mature and ready for production, the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits. Commencing commercial production will require project financing.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic feedstock suppliers, we anticipate that our profitability will be more consistent. Further, cellulosic biofuels yield much higher incentives than non-cellulosic biofuels.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or up to $1 per gallon for a qualified facility (depending on its carbon index) that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027.

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $67.00 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

At commercial scale, management expects to be able to earn substantial renewable fuel credits and produce sustainable ethanol, sustainable aviation fuel, and other sustainable biofuels more profitably than they could be from existing commercial corn ethanol producers. Cellulosic ethanol comes with a much more valuable D3 RIN credit as compared to the D6 RIN allocated to corn ethanol; cellulosic SAF comes with a very valuable D7 RIN, and cellulosic bio-gasoline comes with a valuable D3 RIN. The Company also expects to receive Clean Fuel Production Credits related to section 45Z of the Inflation Reduction Act, whereas these credits are so far not available for corn ethanol producers; and the Company also plans to pursue Low Carbon Fuel Standard Credits.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the CTS technology or forming joint ventures with foreign domestic partners to build plants.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

9

 

 

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of September 30, 2023, the Company has incurred accumulated losses of $55,331,869. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

10

 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23   7/26/23 
Risk-free interest rate   3.46%   3.77%   3.93%   3.86%
Expected life   5 years    7 years    5 years    10 years 
Expected dividends   0%   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%   87.22%
BIOF common stock fair value  $0.165   $0.170   $0.160   $0.160 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $247,854 as of September 30, 2023 and $222,109 as of December 31, 2022.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the nine months ended September 30, 2023, and September 30, 2022, the amounts charged to research and development expenses were $1,741,318 and $2,070,789, respectively.

 

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

11

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life   September 30, 2023   December 31, 2022 
Building and Improvements   15   $9,370   $9,370 
Machinery and Equipment   10   $791,540   $512,450 
Furniture and Fixtures   5   $13,649   $13,649 
Computer Equipment   3   $11,824   $11,824 
Property and Equipment, gross       $826,383   $547,293 
Less Accumulated Depreciation       $(214,125)  $(127,178)
Property and Equipment       $612,258   $420,115 

 

Total depreciation expense was $89,526 for the nine months ended September 30, 2023.

 

In the nine months ended September 30, 2023, The Company purchased machinery worth $285,538. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $3,500 that originally was purchased for $6,448 and that had accumulated depreciation of $2,579, thereby taking a loss of $369 on the disposal of assets.

 

12

 

 

NOTE 5 – PATENTS

 

The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $247,854 as of September 30, 2023.

 

NOTE 6 – DEBT

 

Notes Payable – Related Parties

 

On August 10, 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $25,000, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants. It may convert into common stock at $0.13/share at the option of the holder for a total of 192,308 shares.

 

In June 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $100,000, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $0.13/share for a total of 769,231 shares.

 

In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $150,000, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.

 

In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $250,000, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $0.13/share for a total of 1,923,077 shares.

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full.

 

13

 

 

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carried an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $39,500. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

14

 

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable  September 30, 2023   December 31, 2022 
Short Term Convertible Note – Related Party, including interest  $371,908   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment, incl interest  $276,944   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,386,984   $2,788,132 

 

Of the $3,386,984 payable as of September 30, 2023, $2,738,132 is due out of future revenue or future profits with no specific due date, and another $275,000 is due only after a significant capital investment. $2,417,502 of the $2,738,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $969,482, consisting of $849,482 due to related parties, and $120,000 due to others.

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of September 30, 2023, the Company had 302,750,963 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the nine months ended September 30, 2023, the Company issued an aggregate of 174,191 shares of its common stock for services valued at $29,300.

 

For the nine months ended September 30, 2023, 364,000 warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $48,447.

 

For the nine months ended September 30, 2023, 6,684,998 shares of common stock were issued for cash of $1,002,772.

 

For the nine months ended September 30, 2023, 5,950,148 warrants were exercised for proceeds of $97,250.

 

For the nine months ended September 30, 2023, 2,067,999 warrants expired.

 

For the nine months ended September 30, 2023, 7,050,000 unvested options expired and 125,000 vested options expired.

 

For the nine months ended September 30, 2023, 4,385,000 stock options vested. Using a Black-Scholes asset pricing model, these had a value of $637,028.

 

For the nine months ended September 30, 2023, 17,150,000 stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $2,835,613.

 

15

 

 

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.

 

Cybersecurity

 

No material cybersecurity breach has occurred.

 

Leases

 

The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. Annual rent commenced at $84,100 per annum and increased 3% per year. The latest amendment adjusted the lease to $102,950 per annum and increases at 3% per year. Tenant is also required to cover operating costs that are estimated at $3,600 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for 18.2 acres at an annual cost of $6,370 that the Company has the right to renew for a total of 5 years. A second lease began on March 31, 2023, for an additional 167.6 acres at a cost of $24,721 every 6 months that the Company also can continue for up to 5 years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.

 

Rent expense for the nine months ending September 30, 2023, and 2022, were $183,537 and $106,631, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED  September 30, 2023   December 31, 2022 
Right of Use Lease Liabilities          
Current portion   101,905    95,172 
Long-term portion   8,793    85,983 
TOTAL   110,698    181,155 

 

As of September 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   24,715 
2024   85,983 
2025   0 
      
TOTAL  $110,698 

 

16

 

 

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From October 1, 2023, to the date of this filing, the Company issued 350,000 warrants for services. Using the Black-Scholes pricing model, these were valued at $29,991.

 

From October 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $15,000.

 

17

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

The following discussion should be read in conjunction with the Company’s audited financial statements and the notes thereto.

 

Forward-Looking Statements

 

This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

 

Business Overview

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new reactor technology with a higher yield and a continuous throughput in the Cellulose-to-Sugar process, or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with the technical staff of the Company. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in Japan and El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

18

 

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

The Company believes a significant difference between CTS cellulosic ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant.

 

The Company believes that it can optimize the pre and post processing elements at this pilot scale plant to finalize design and operational parameters to provide operating cost estimates of a full-scale commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

19

 

 

In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline. The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

Plan of Operation

 

The total process from cellulosic feedstock to SAF consists basically of three steps:

 

  4) Conversion from feedstock to fermentable cellulosic sugars (CTS)
  5) Ferment the cellulosic sugars into cellulosic ethanol.
  6) Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed.

 

Given the fact that the Vertimass technology is mature and ready for production, the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits. Commencing commercial production will require project financing.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic feedstock suppliers, we anticipate that our profitability will be more consistent. Further, cellulosic biofuels yield much higher incentives than non-cellulosic biofuels.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or up to $1 per gallon for a qualified facility (depending on its carbon index) that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027.

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $67.00 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

At commercial scale, management expects to be able to earn substantial renewable fuel credits and produce sustainable ethanol, sustainable aviation fuel, and other sustainable biofuels more profitably than they could be from existing commercial corn ethanol producers. Cellulosic ethanol comes with a much more valuable D3 RIN credit as compared to the D6 RIN allocated to corn ethanol; cellulosic SAF comes with a very valuable D7 RIN, and cellulosic bio-gasoline comes with a valuable D3 RIN. The Company also expects to receive Clean Fuel Production Credits related to section 45Z of the Inflation Reduction Act, whereas these credits are so far not available for corn ethanol producers; and the Company also plans to pursue Low Carbon Fuel Standard Credits.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the CTS technology or forming joint ventures with foreign domestic partners to build plants.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

20

 

 

Capital Formation

 

From January 1, 2023, through the date of filing, the Company issued an aggregate of 174,194 shares of its common stock for services valued at $29,300.

 

From January 1, 2023, through the date of filing, the Company issued an aggregate of 714,000 warrants for services valued at $78,438.

 

From January 1, 2023, through the date of filing, the Company issued an aggregate of 6,684,998 shares of its common stock for capital of $1,002,772.

 

From January 1, 2023, through the date of filing, 5,950,148 warrants were exercised for $97,250.

 

From January 1, 2023, through the date of filing, the Company issued unvested options to its managers and employees to purchase 17,150,000 shares of its common stock for a period of ten years at the exercise price of 16 to 20 cents per share. Using a Black-Scholes asset-pricing model, these agreements were valued at $2,835,613. None of those have vested. 1,000,000 vested options were issued at exercise prices between 16 and 19 cents. 3,385,000 previously issued options have vested. Using a Black-Scholes option pricing model, these vested options have a valuation of $637,028.

 

From January 1, 2023, through the date of filing, 7,175,000 options expired or were cancelled and 2,067,999 warrants expired.

 

Going Concern

 

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further capital. As of September 30, 2023, the Company had a working capital deficit of $1,066,285 and had incurred accumulated losses of $55,331,869 since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, there is substantial doubt about the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses.

 

Results of Operations

 

Comparison of the three and nine month period ended September 30, 2023 (unaudited) to September 30, 2022

 

For the three and nine months ended September 30, 2023, the Company recognized $0 in revenue as opposed to $0 in 2022.

 

For the three months ended September 30, 2023, the Company’s general and administrative expenses increased by $40,648 to $219,160 from $178,512 in 2022. This increase is primarily the result of a $119,600 employee retention credit issued in 2022 related to COVID, versus $0 in 2023.

 

For the nine months ended September 30, 2023, the Company’s general and administrative expenses decreased by $279,131 to $943,953 from $1,223,083 in 2022. This decrease is primarily the result of $169,382 in equity-based compensation versus $506,975 in 2022.

 

Interest expense decreased in the quarter ended September 30, 2023 by $10,362 to $25,661 from $36,024 in 2022. Interest expense increased in the nine months ended September 30, 2023 by $20,075 to $71,144 from $51,069 in 2022.

 

For the nine months ended September 30, 2023 the Company recorded non-cash impairments of assets of $369 as compared to $40,099 in 2022. This was the result of disposing and/or selling of laboratory assets no longer in use in each year.

 

Research and development (R&D) costs for the quarter ended September 30, 2023 were $293,674, a decrease of $110,483 from $404,157 in 2022. The decrease in R&D expenses is primarily the result of equity based compensation of $0 versus $99,479 in 2022.

 

21

 

 

Research and development (R&D) costs for the nine months ended September 30, 2023 were $1,741,318, a decrease of $329,471 from $2,070,789 in 2022. The decrease in R&D expenses is primarily the result of a decrease in equity based compensation to $467,646 from $1,019,330 in 2022 due to the vesting of more options in 2022.

 

Liquidity and Capital Resources

 

Liquidity

 

As of September 30, 2023, the Company had $84,663 in cash, and total stockholders’ equity on September 30, 2023, was negative $3,092,403. As of December 31, 2022, the Company had $211,901 in cash, and total stockholders’ equity at December 31, 2022, was negative $2,356,917. Total debt, including advances, accounts payable and other notes payable at September 30, 2023, together with interest payable thereon and contingent liabilities, was $4,341,916 an increase of $879,080 from December 31, 2022, where it stood at $3,462,836. This increase is primarily attributable to new convertible notes due to related parties. $1,820,630 of the remaining debt has been renegotiated to be payable out of future revenue and $917,502 out of future profits and otherwise does not come due.

 

During the nine months ended September 30, 2023, the Company’s net cash used in operating activities decreased by $91,776 to $1,494,477 from $1,586,253 in the nine months ending September 30, 2022.

 

During the nine months ended September 30, 2023, the Company’s investing activities used $307,782 in cash, as compared to $104,301 in the first nine months of 2022. This can be primarily attributed to capitalizing $25,744 in patent costs and $282,038 used to purchase machinery and equipment, as compared to $42,501 in patent costs and $61,800 in net purchases of equipment in the first nine months of 2022.

 

During the nine months ended September 30, 2023, the Company generated an aggregate of $1,675,022 through its financing activities versus $1,030,900 in the nine months ended September 30, 2022, which is an increase of $644,122. This increase from the prior year can primarily be attributed to the issuance of $625,000 in convertible notes to related parties in 2023.

 

Capital Resources

 

At this time, the Company has limited liquidity and capital resources. To continue funding its operations, the Company will need to generate revenue or obtain additional financing for current and future operations. The Company anticipates needing additional funds for G&A expenses and will seek project financing for a commercial ethanol to SAF facility in addition to funds needed to complete the commercialization of its CTS system. There is no guarantee that the Company will achieve all of the additional funding that is needed.

 

As of the date of this filing, the Company has raised $1,100,022 in 2023, through the issuance of shares and the exercise of warrants, plus $15,863,601 raised previously, in addition to capital raised through debt or convertible notes including $625,000 raised through convertible notes in 2023. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company.

 

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

 

Equity

 

As of September 30, 2023, shareholders’ equity was negative $3,092,403.

 

There were 302,750,963 shares of common stock issued and outstanding as of September 30, 2023.

 

There were no preferred shares outstanding.

 

The Company has paid no dividends.

 

22

 

 

Critical Accounting Policies

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Seasonality

 

The Company’s operating results are not affected by seasonality.

 

Inflation

 

The Company’s business and operating results are not affected in any material way by inflation.

 

Contractual Obligations

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Disclosure controls and procedures refer to controls and other procedures designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

As required by Rule 13a-15(e) of the Exchange Act, our management has carried out an evaluation, with the participation and under the supervision of our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as of December 31, 2022. Based upon, and as of the date of this evaluation, our chief executive officer and chief financial officer determined that our disclosure controls and procedures were sufficient.

 

Changes in Internal Control over Financial Reporting

 

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of December 31, 2022, that occurred during our first three fiscal quarters pf 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

23

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.

 

ITEM 1A. RISK FACTORS.

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

 

Below is a list of securities sold by the Company from January 1, 2023, through the date of filing which were not registered under the Securities Act.

 

Entity  Date of Investment 

Title of

Security

  Amount of Securities Sold   Consideration
Raymond Leon  01/03/23  Common Stock   200,000   Purchased @ $0.15 per share
James Cherwin  01/30/23  Common Stock   100,000   Purchased @ $0.15 per share
Edmund Burke  01/30/23  Common Stock   4,450,148   Exercise of Warrants
Edmund Burke  01/31/23  Common Stock   1,000,000   Exercise of Warrants
NWBB, Inc  02/06/23  Common Stock   40,000   Professional Services
Ron Smith  02/06/23  Common Stock   166,666   Purchased @ $0.15 per share
Mark Monahan  02/17/23  Common Stock   333,333   Purchased @ $0.15 per share
Michael Fidler  02/17/23  Common Stock   200,000   Purchased @ $0.15 per share
Joseph Corry  02/17/23  Common Stock   100,000   Purchased @ $0.15 per share
William Newman  02/21/23  Common Stock   100,000   Purchased @ $0.15 per share
Johnny Anastasiades  03/01/23  Common Stock   135,000   Purchased @ $0.15 per share
Jozef Kneppers  03/06/23  Common Stock   1,333,333   Purchased @ $0.15 per share
James Dupre & Michelle Dupre  03/06/23  Common Stock   150,000   Purchased @ $0.15 per share
Randall Brodsky  03/07/23  Common Stock   400,000   Purchased @ $0.15 per share
Tamara Chapman Revocable Trust  03/08/23  Common Stock   333,333   Purchased @ $0.15 per share
John Comrie  03/08/23  Common Stock   333,333   Purchased @ $0.15 per share
William Fitzpatrick  03/24/23  Common Stock   100,000   Professional Services
Neil Hendry  04/05/23  Common Stock   66,667   Purchased @ $0.15 per share
NWBB, Inc.  04/10/23  Common Stock   34,194   Professional Services
Clay Taylor  04/11/23  Common Stock   400,000   Purchased @ $0.15 per share
Kophyo Win  05/05/23  Common Stock   166,667   Purchased @ $0.15 per share
Patrick Simms  05/15/23  Common Stock   500,000   Exercise of Warrants
Mark Monahan  07/19/23  Common Stock   166,667   Purchased @ $0.15 per share
Anthony Santelli  07/26/23  Common Stock   333,333   Purchased @ $0.15 per share
Kevin McNally  08/11/23  Common Stock   333,333   Purchased @ $0.15 per share
Melvin Eaton  08/15/23  Common Stock   333,333   Purchased @ $0.15 per share
Craig Roger Tarr  08/24/23  Common Stock   1,000,000   Purchased @ $0.15 per share

 

The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(a)(2) of that Act and Rules 504 and 506 of Regulation D.

 

24

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

The exhibits listed below are filed as part of or incorporated by reference in this report.

 

Exhibit No.   Identification of Exhibit
     
2.1   Chapter 11 Plan of Reorganization (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
2.2   Chapter 11 Disclosure Statement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.1   Articles of Incorporation (incorporated by reference to the Company’s S-1 filed May 23, 2021)
     
3.2   Certificate of Amendment to Articles of Incorporation filed November 19, 2014 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.3   Certificate of Amendment to Articles of Incorporation filed June 17, 2016 (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
3.4   Certificate of Amendment to Articles of Incorporation filed July 26, 2021 (incorporated by reference to the Company’s 8-K filed on July 30, 2021)
     
3.5   Bylaws (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.1   Lease Agreement (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.2   Employment Agreement, dated June 1, 2020, between the Company and Ben Slager (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021)
     
10.3   Employment Agreement, dated June 1, 2020, between the Company and Anthony Santelli (incorporated by reference to the Company’s Form 10-12G/A filed on February 16, 2021
     
10.4   2021 Employee, Director Stock Plan (incorporated by reference to definitive 14C filed with the SEC on June 24, 2021)
     
31.1.   Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2   Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
     
101.SCH   Inline XBRL Taxonomy Extension Schema Document
     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

25

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Blue Biofuels, Inc.
  (Registrant)
   
  By /s/ Benjamin Slager
    Benjamin Slager
    Chief Executive Officer, (Principal Executive Officer)
     
  Date  November 13, 2023
     
  By /s/ Anthony Santelli
    Anthony Santelli
    Chief Financial Officer (Principal Financial and Accounting Officer)
     
  Date  November 13, 2023

 

26

 

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATIONS

 

I, Benjamin Slager, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
       
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 13, 2023

 

/s/ Benjamin Slager  
Benjamin Slager  

Chief Executive Officer

(Principal Executive Officer)

  

 

 

 

 EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATIONS

 

I, Anthony Santelli, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Blue Biofuels, Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
       
    a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
       
    b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
       
    c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
       
    d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
       
  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
       
    a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
       
    b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 13, 2023

 

/s/ Anthony Santelli  
Anthony Santelli  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Benjamin Slager, the Chief Executive Officer of Blue Biofuels, Inc (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 13th day of November, 2023.

 

  /s/ Benjamin Slager
  Benjamin Slager
 

Chief Executive Officer

(Principal Executive Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

The undersigned, Anthony Santelli, the Chief Financial Officer of Blue Biofuels, Inc. (the “Company”), DOES HEREBY CERTIFY that:

 

1. The Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

IN WITNESS WHEREOF, the undersigned has executed this statement this 13th day of November, 2023.

 

  /s/ Anthony Santelli
  Anthony Santelli
 

Chief Financial Officer

(Principal Financial and Accounting Officer)

 

A signed original of this written statement required by Section 906 has been provided to Blue Biofuels, Inc. and will be retained by Blue Biofuels, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

 EX-101.SCH 6 biof-20230930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statement of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - PATENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - DEBT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 biof-20230930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 biof-20230930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 biof-20230930_lab.xml XBRL LABEL FILE Related Party Transaction [Axis] Nonrelated Party [Member] Related Party [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Concentration Risk Benchmark [Axis] Cost of Goods and Service, Product and Service Benchmark [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Legal Entity [Axis] Vertimass Technology [Member] Award Date [Axis] Issuance Date 2/10/23 [Member] Warrant [Member] Issuance Date 2/14/23 [Member] Issuance Date 3/1/23 [Member] Issuance Date 3/31/2023 [Member] Issuance Date 4/5/23 [Member] Issuance Date 4/11/23 [Member] Issuance Date 4/26/23 [Member] Issuance Date 6/5/23 [Member] Issuance Date 7/13/23 [Member] Issuance Date 7/26/23 [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Long-Lived Tangible Asset [Axis] Building Improvements [Member] Machinery and Equipment [Member] Furniture and Fixtures [Member] Computer Equipment [Member] Pilot Plant [Member] Machinery [Member] Related Party, Type [Axis] Edmund Burke [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] Chris Kneppers [Member] Short-Term Debt, Type [Axis] Convertible Debt One [Member] Convertible Debt Two [Member] Business Acquisition [Axis] AMG Energy Group [Member] Mark Koch [Member] Animated Family Films [Member] Steven Dunkle CTWC Wellington Asset Holdings [Member] Steven Sadaka [Member] Loans Payable [Member] Inducement Shares [Member] Christopher Jemapete [Member] Pamela Jemapete [Member] Notes Payable, Other Payables [Member] Lucas Hoppel [Member] Other Related Party [Member] Office and Laboratory Space [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] ASSETS Current assets Cash and cash equivalents Grants receivable Prepaid expenses TOTAL CURRENT ASSETS Long-term assets Property and equipment, net of accumulated depreciation and amortization of $214,125 and $127,178 at September 30, 2023 and December 31,2022, respectively Security deposits Right of Use Assets, net of accumulated amortization Patents TOTAL LONG-TERM ASSETS TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities Accounts payable Deferred wages and director’s fees - Related party Lease Liability - Current Chapter 11 Settlement Convertible Notes Payable — Related Party Interest Payable - Related Party TOTAL CURRENT LIABILITIES Long term liabilities Right of Use Lease Liability, net of current portion Notes Payable — Related Party Notes Payable — Other TOTAL LONG TERM LIABILITIES TOTAL LIABILITIES STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding Common stock; $0.001 par value; 1,000,000,000 shares authorized; 302,750,963 issued and outstanding at September 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022. Additional paid-in capital Accumulated deficit Total stockholders’ equity (deficit) TOTAL EQUITY (DEFICIT) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Statement of Financial Position [Abstract] Accumulated depreciation and amortization on property and equipment Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Revenues Operating expense: General and administrative Research & Development Loss on disposal of assets Total operating expenses Loss from operations: Other (income) expense: Grants received Interest expense - related party Interest expense - other Total other (income) expense Income (Loss) before provisions for income taxes Provisions for income taxes Net Income / (Loss): Net income (loss) per share Basic and Diluted Earnings per share Weighted average common shares outstanding - Basic Weighted average common shares outstanding - Fully Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Issuance of common stock for services Issuance of common stock for services, shares Issuance of common stock and warrants for cash through PPM Issuance of common stock and warrants for cash through PPM, shares Warrants exercised Warrants exercised, shares Vesting of options under the employee, director plan Net Income (Loss) Issuance of warrants for services Employee stock options exercised Employee stock options exercised, shares Balance Balance, shares Statement of Stockholders' Equity [Abstract] Vesting of options previously issued under employee director plan Warrants issued for services Statement of Cash Flows [Abstract] Cash flows from operating activities Reconciliation of net loss to net cash used in operating activities Depreciation and amortization Stock based compensation for services Net Issuance of options and warrants for services Loss on Disposal of assets Changes in operating assets and liabilities Prepaid expenses Grants receivable Accrued interest - related party Accounts payable and accrued liabilities Right of use lease Net cash used in operating activities Cash flows from investing activities Net Purchase of property and equipment Patent Costs Net cash from (used in) investing activities Cash flows from financing activities Proceeds from exercise of warrants and options Net Proceeds from the issuance of Convertible Notes Net proceeds from issuance of common stock Payment of Debt Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalent at beginning of the period Cash and cash equivalent at end of the period Supplemental disclosure of cash flow information Cash paid during the period for Interest Taxes Supplemental schedule of non-cash activities Issuance of warrants for services Issuance of common stock for services Cashless conversion of warrants/options Conversion of convertible debenture to common stock Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION GOING CONCERN Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] PATENTS Debt Disclosure [Abstract] DEBT Equity [Abstract] STOCKHOLDERS’ EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Use of Estimates Cash and Cash Equivalents Stock Compensation Stock-based Compensation Valuation Methodology Property and Equipment Patent Capitalization Research and Development Revenue Recognition Common Stock Purchase Warrants and Other Derivative Financial Instruments Impairment of Long-Lived Assets Income Taxes Profit (Loss) per Common Share: Fair Value Measurements Recent Accounting Pronouncements SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF NOTES PAYABLE SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Schedule of Product Information [Table] Product Information [Line Items] Dscription of Production Renewable fuel description Accumulated losses Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Risk-free interest rate Expected life Expected dividends Expected volatility BIOF common stock fair value Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, estimated useful life Research and development expenses Property and Equipment, gross Estimated Useful Lives Less Accumulated Depreciation Property and Equipment Depreciation Purchase of machinery Disposal of machinery Purchase value Accumulated depreciation Loss on disposal of assets Finite-Lived Patents, Gross Short Term Convertible Note – Related Party, including interest Short Term Chapter 11 Settlement Long Term Notes Payable after capital investment, incl interest Long Term Notes Payable from future revenue — Related Party Long Term Notes Payable from future revenue — Other Long Term Note Payable from future profits — Related Party Long Term Note Payable from future profits — Other TOTAL NOTES Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Debt instrument principal amount Debt interest rate Debt instrument, description Debt instrument, term Shares, conversion of convertible securities Warrant, reason for issuance, description Convertible, conversion price per share Renegotiated notes, description Renegotiated amount Debt instrument maturity date Conversion of convertible securities, value Amount to be paid out of future gross revenues Accrued interest, value Business acquisition, percentage Original issue discount Debt instrument conversion discount rate, percentage Debt instrument principal payments TOTAL NOTES Percentage of future gross revenue Notes payable, noncurrent Due out of long term future revenue Due related to long term notes payable capital investment Notes payable amount to be discharged Due to related parties Capital units, authorized Preferred stock, shares Issued Number of shares issued for services, shares Number of shares issued for services, value Warrants issued for services, value Warrants exercised share, shares Number of warrants expired Unvested options expired Unvested options expired Number of stock options vested, shares Number of stock options vested, value Number of shares unvested Options issued and unvested value Current portion Long-term portion TOTAL 2023 2024 2025 TOTAL Lease extension period Annual rent Percentage of increase in rent per year Lease expense Operating costs Acres Lease cost Lease renewal term Rent expense Subsequent Event [Table] Subsequent Event [Line Items] Warrants issued for services, shares Warrants issued for services Convertible note Stockholders Equity Deficit. Grants received. Issuance of common stock and warrants for cash through ppm. Issuance of common stock and warrants for cash through Ppm shares. Warrants exercised. Warrants exercised share. Warrants issued for service. Stock issued during period value stock options exercised1. Stock issued during period shares stock options exercised. Increase decrease in grants receivable. Increase decrease in right of use lease. Payments for patent costs. Cashless conversion of warrants. Conversion of convertible debenture to common stock. Issuance of warrants for services. Issuance of common stock for services. Renewable Fuel Description. Stock based Compensation Valuation Methodology [Policy Text Block] Issuance Date February Ten Two Thousand Twenty Three [Member] Issuance Date February Fourteen Two Thousand Twenty Three [Member] Issuance Date March One Two Thousand Twenty Three [Member] Issuance Date March Thirty First Two Thousand Twenty Three [Member] Issuance Date April Five Two Thousand Twenty Three [Member] Issuance Date April Eleven Two Thousand Twenty Three [Member] Issuance Date April Twenty Six Two Thousand Twenty Three [Member] Issuance Date June Five Two Thousand Twenty Three [Member] Issuance Date July Thirteen Two Thousand Twenty Three [Member] Issuance Date 7/26/23 [Member] Common Stock Purchase Warrants And Other Derivative Financial Instruments [Policy Text Block] Pilot Plant [Member] Machinery [Member] Edmund Burke [Member] Chris Kneppers [Member] Convertible Debt One [Member] Convertible Debt Two [Member] AMG Energy Group [Member] Renegotiated notes description. Renegotiated amount. Mark Koch [Member] Animated Family Films [Member] Steven Dunkle CTWC Wellington Asset Holdings [Member] Steven Sadaka [Member] Inducement Shares [Member] Amount to be paid out of future gross revenues. Christopher Jemapete [Member] Pamela Jemapete [Member] Lucas Hoppel [Member] Percentage of future gross revenue. Long term notes payable after capital investment received. Long term notes payable from future revenue related party. Long Term Notes Payable From Future Revenue Other. Long term note payable from future profits related party. Long term note payable from future profits other. Due out of long term future revenue. Due related to long term notes payable capital investment. Notes payable amount to be discharged. Other Related Party [Member] Warrants issued during period value issued for services. Sharebased compensation arrangement by sharebased payment award options issued and unvested in period fair value. Share based compensation arrangement by share based payment award vested options expirations in period. Office and Laboratory Space [Member] Annual rent. Percentage of increase in rent per year. Lease renewal term. Vertimass Technology [Member] Assets, Current Assets, Noncurrent Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Stockholders Equity Deficit Liabilities and Equity Gain (Loss) on Disposition of Assets Operating Expenses Operating Income (Loss) GrantsReceived Nonoperating Income (Expense) Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Prepaid Expense IncreaseDecreaseInGrantsReceivable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment PaymentsForPatentCosts Net Cash Provided by (Used in) Investing Activities Repayments of Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations IssuanceOfWarrantsForServices IssuanceOfCommonStockForServices ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod Operating Lease, Liability Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 10 biof-20230930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 10, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 000-54942  
Entity Registrant Name BLUE BIOFUELS, INC.  
Entity Central Index Key 0001549145  
Entity Tax Identification Number 45-4944960  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 3710 Buckeye Street  
Entity Address, Address Line Two Suite 120  
Entity Address, City or Town Palm Beach Gardens  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33410  
City Area Code (888)  
Local Phone Number 607-3555  
Title of 12(b) Security Common Stock par value $0.001  
Trading Symbol BIOF  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   302,750,963
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 84,663 $ 211,901
Grants receivable 130,835  
Prepaid expenses 38,209 43,119
TOTAL CURRENT ASSETS 253,707 255,020
Long-term assets    
Property and equipment, net of accumulated depreciation and amortization of $214,125 and $127,178 at September 30, 2023 and December 31,2022, respectively 612,258 420,115
Security deposits 30,276 30,276
Right of Use Assets, net of accumulated amortization 105,418 178,399
Patents 247,854 222,109
TOTAL LONG-TERM ASSETS 995,806 850,899
TOTAL ASSETS 1,249,513 1,105,919
Current liabilities    
Lease Liability - Current 101,905 95,172
Chapter 11 Settlement 50,000
Interest Payable - Related Party 120,124 76,138
TOTAL CURRENT LIABILITIES 1,319,991 638,721
Long term liabilities    
Right of Use Lease Liability, net of current portion 8,793 85,983
Notes Payable — Other 216,570 216,570
TOTAL LONG TERM LIABILITIES 3,021,925 2,824,115
TOTAL LIABILITIES 4,341,916 3,462,836
STOCKHOLDERS’ EQUITY (DEFICIT)    
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding
Common stock; $0.001 par value; 1,000,000,000 shares authorized; 302,750,963 issued and outstanding at September 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022. 302,751 289,942
Additional paid-in capital 51,936,716 50,134,727
Accumulated deficit (55,331,869) (52,781,586)
Total stockholders’ equity (deficit) (3,092,403) (2,356,917)
TOTAL EQUITY (DEFICIT) (3,092,403) (2,356,917)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 1,249,513 1,105,919
Nonrelated Party [Member]    
Current liabilities    
Accounts payable 698 37,135
Related Party [Member]    
Current liabilities    
Accounts payable 72,670 72,670
Deferred wages and director’s fees - Related party 674,594 307,606
Convertible Notes Payable — Related Party 350,000
Long term liabilities    
Notes Payable — Related Party $ 2,796,562 $ 2,521,562
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Accumulated depreciation and amortization on property and equipment $ 214,125 $ 127,178
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 302,750,963 289,941,623
Common stock, shares outstanding 302,750,963 289,941,623
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statement of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Related Party Transaction [Line Items]        
Revenues
Operating expense:        
General and administrative 219,160 178,512 943,953 1,223,083
Research & Development 293,674 404,157 1,741,318 2,070,789
Loss on disposal of assets 369 40,099
Total operating expenses 512,834 582,669 2,685,640 3,333,971
Loss from operations: (512,834) (582,669) (2,685,640) (3,333,971)
Other (income) expense:        
Interest expense - other 2,443 29,313 7,431 30,934
Total other (income) expense (180,839) 36,024 (135,357) 51,069
Income (Loss) before provisions for income taxes (331,995) (618,693) (2,550,283) (3,385,040)
Provisions for income taxes    
Net Income / (Loss): $ (331,995) $ (618,693) $ (2,550,283) $ (3,385,040)
Net income (loss) per share $ (0.001) $ (0.002) $ (0.008) $ (0.012)
Basic and Diluted Earnings per share $ (0.001) $ (0.002) $ (0.008) $ (0.012)
Weighted average common shares outstanding - Basic 302,750,963 277,416,282 302,750,963 277,416,282
Weighted average common shares outstanding - Fully Diluted 302,750,963 277,416,282 302,750,963 277,416,282
Related Party [Member]        
Other (income) expense:        
Grants received $ (206,500) $ (206,500)
Interest expense - related party $ 23,218 $ 6,711 $ 63,712 $ 20,135
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 274,004 $ 47,151,353 $ (48,821,403) $ (1,396,046)
Balance, shares at Dec. 31, 2021 274,003,883        
Issuance of common stock for services $ 448 70,852 71,300
Issuance of common stock for services, shares 447,781        
Vesting of options under the employee, director plan   1,316,277 1,316,277
Net Income (Loss)       (2,040,957) (2,040,957)
Employee stock options exercised $ 150 7,350 7,500
Employee stock options exercised, shares 150,000        
Balance at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Balance, shares at Mar. 31, 2022 274,601,664        
Balance at Dec. 31, 2021 $ 274,004 47,151,353 (48,821,403) (1,396,046)
Balance, shares at Dec. 31, 2021 274,003,883        
Net Income (Loss)         (3,385,040)
Balance at Sep. 30, 2022 $ 281,817 49,822,662 (52,206,443) (2,101,964)
Balance, shares at Sep. 30, 2022 281,815,770        
Balance at Mar. 31, 2022 $ 274,602 48,545,832 (50,862,360) (2,041,926)
Balance, shares at Mar. 31, 2022 274,601,664        
Issuance of common stock for services $ 79 16,071 16,150
Issuance of common stock for services, shares 78,600        
Issuance of common stock and warrants for cash through PPM $ 4,500 670,500 675,000
Issuance of common stock and warrants for cash through PPM, shares 4,499,999        
Vesting of options under the employee, director plan   99,106 99,106
Net Income (Loss)       (725,390) (725,390)
Employee stock options exercised $ 200 8,200 8,400
Employee stock options exercised, shares 200,000        
Balance at Jun. 30, 2022 $ 279,380 49,339,710 (51,587,750) (1,968,660)
Balance, shares at Jun. 30, 2022 279,380,263        
Issuance of common stock for services $ 169 28,981 29,150
Issuance of common stock for services, shares 168,842        
Issuance of common stock and warrants for cash through PPM $ 2,267 337,733 340,000
Issuance of common stock and warrants for cash through PPM, shares 2,266,665        
Vesting of options under the employee, director plan 110,922 110,922
Net Income (Loss)       (618,693) (618,693)
Issuance of warrants for services   5,317 5,317
Balance at Sep. 30, 2022 $ 281,817 49,822,662 (52,206,443) (2,101,964)
Balance, shares at Sep. 30, 2022 281,815,770        
Balance at Dec. 31, 2022 $ 289,942 50,134,727 (52,781,586) (2,356,917)
Balance, shares at Dec. 31, 2022 289,941,623        
Issuance of common stock for services $ 140 23,860 24,000
Issuance of common stock for services, shares 140,000        
Issuance of common stock and warrants for cash through PPM $ 3,885 578,865 582,750
Issuance of common stock and warrants for cash through PPM, shares 3,884,998        
Warrants exercised $ 5,450 66,800 72,250
Warrants exercised, shares 5,450,148        
Vesting of options under the employee, director plan   391,297 391,297
Net Income (Loss)       (1,064,090) (1,064,090)
Balance at Mar. 31, 2023 $ 299,417 51,195,549 (53,845,676) (2,350,710)
Balance, shares at Mar. 31, 2023 299,416,769        
Balance at Dec. 31, 2022 $ 289,942 50,134,727 (52,781,586) (2,356,917)
Balance, shares at Dec. 31, 2022 289,941,623        
Issuance of common stock for services         $ 29,300
Issuance of common stock for services, shares         174,191
Issuance of common stock and warrants for cash through PPM         $ 1,002,772
Issuance of common stock and warrants for cash through PPM, shares         6,684,998
Warrants exercised         $ 97,250
Warrants exercised, shares         5,950,148
Net Income (Loss)         $ (2,550,283)
Balance at Sep. 30, 2023 $ 302,751 51,936,715 (55,331,870) (3,092,403)
Balance, shares at Sep. 30, 2023 302,750,963        
Balance at Mar. 31, 2023 $ 299,417 51,195,549 (53,845,676) (2,350,710)
Balance, shares at Mar. 31, 2023 299,416,769        
Issuance of common stock for services $ 34 5,266 5,300
Issuance of common stock for services, shares 34,194        
Issuance of common stock and warrants for cash through PPM $ 633 94,389 95,022
Issuance of common stock and warrants for cash through PPM, shares 633,334        
Warrants exercised $ 500 24,500 25,000
Warrants exercised, shares 500,000        
Vesting of options under the employee, director plan   245,732 245,732
Net Income (Loss)       (1,154,199) (1,154,199)
Issuance of warrants for services   42,634 42,634
Balance at Jun. 30, 2023 $ 300,584 51,608,069 (54,999,875) (3,091,221)
Balance, shares at Jun. 30, 2023 300,584,297        
Issuance of common stock and warrants for cash through PPM $ 2,167   322,833   325,000
Issuance of common stock and warrants for cash through PPM, shares 2,166,666        
Net Income (Loss)       (331,995) (331,995)
Issuance of warrants for services   5,813   5,813
Balance at Sep. 30, 2023 $ 302,751 $ 51,936,715 $ (55,331,870) $ (3,092,403)
Balance, shares at Sep. 30, 2023 302,750,963        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]              
Vesting of options previously issued under employee director plan   2,000,000 2,385,000 825,000 800,000 10,560,000 4,385,000
Warrants issued for services 50,000 314,000   37,333     364,000
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net Income (Loss) $ (2,550,283) $ (3,385,040)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 89,526 102,711
Stock based compensation for services 29,300 116,600
Net Issuance of options and warrants for services 685,474 1,531,622
Loss on Disposal of assets 369 40,099
Changes in operating assets and liabilities    
Prepaid expenses 4,910 (41,729)
Grants receivable (130,835)  
Accrued interest - related party 43,986 20,135
Accounts payable and accrued liabilities 330,551 62,996
Right of use lease 2,525 (33,647)
Net cash used in operating activities (1,494,477) (1,586,253)
Cash flows from investing activities    
Net Purchase of property and equipment (282,038) (61,800)
Patent Costs (25,744) (42,501)
Net cash from (used in) investing activities (307,782) (104,301)
Cash flows from financing activities    
Proceeds from exercise of warrants and options 97,250 15,900
Net Proceeds from the issuance of Convertible Notes 625,000  
Net proceeds from issuance of common stock 1,002,772 1,015,000
Payment of Debt (50,000)  
Net cash provided by financing activities 1,675,022 1,030,900
Net increase (decrease) in cash and cash equivalents (127,237) (659,653)
Cash and cash equivalent at beginning of the period 211,901 1,164,664
Cash and cash equivalent at end of the period 84,663 505,010
Cash paid during the period for    
Interest
Taxes
Supplemental schedule of non-cash activities    
Issuance of warrants for services 48,447 5,317
Issuance of common stock for services 29,300 116,600
Cashless conversion of warrants/options
Conversion of convertible debenture to common stock
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
ORGANIZATION
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION

NOTE 1 – ORGANIZATION

 

Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.

 

In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new reactor technology with a higher yield and a continuous throughput in the Cellulose-to-Sugar process, or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with the technical staff of the Company. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in Japan and El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.

 

Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.

 

The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.

 

CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.

 

The Company believes a significant difference between CTS cellulosic ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre.

 

In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.

 

In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. The Company believes that it can optimize the pre and post processing elements at this pilot scale plant to finalize design and operational parameters to provide operating cost estimates of a full-scale commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.

 

 

In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline. The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.

 

Plan of Operation

 

The total process from cellulosic feedstock to SAF consists basically of three steps:

 

  1) Conversion from feedstock to fermentable cellulosic sugars (CTS)
  2) Ferment the cellulosic sugars into cellulosic ethanol.
  3) Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed.

 

Given the fact that the Vertimass technology is mature and ready for production, the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits. Commencing commercial production will require project financing.

 

Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.

 

The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic feedstock suppliers, we anticipate that our profitability will be more consistent. Further, cellulosic biofuels yield much higher incentives than non-cellulosic biofuels.

 

The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.

 

Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or up to $1 per gallon for a qualified facility (depending on its carbon index) that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027.

 

A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $67.00 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.

 

At commercial scale, management expects to be able to earn substantial renewable fuel credits and produce sustainable ethanol, sustainable aviation fuel, and other sustainable biofuels more profitably than they could be from existing commercial corn ethanol producers. Cellulosic ethanol comes with a much more valuable D3 RIN credit as compared to the D6 RIN allocated to corn ethanol; cellulosic SAF comes with a very valuable D7 RIN, and cellulosic bio-gasoline comes with a valuable D3 RIN. The Company also expects to receive Clean Fuel Production Credits related to section 45Z of the Inflation Reduction Act, whereas these credits are so far not available for corn ethanol producers; and the Company also plans to pursue Low Carbon Fuel Standard Credits.

 

After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the CTS technology or forming joint ventures with foreign domestic partners to build plants.

 

The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.

 

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
GOING CONCERN
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2 – GOING CONCERN

 

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of September 30, 2023, the Company has incurred accumulated losses of $55,331,869. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

 

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23   7/26/23 
Risk-free interest rate   3.46%   3.77%   3.93%   3.86%
Expected life   5 years    7 years    5 years    10 years 
Expected dividends   0%   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%   87.22%
BIOF common stock fair value  $0.165   $0.170   $0.160   $0.160 

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $247,854 as of September 30, 2023 and $222,109 as of December 31, 2022.

 

Research and Development

 

The Company expenses all research and development costs as incurred. For the nine months ended September 30, 2023, and September 30, 2022, the amounts charged to research and development expenses were $1,741,318 and $2,070,789, respectively.

 

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

 

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

 
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

NOTE 4 – PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life   September 30, 2023   December 31, 2022 
Building and Improvements   15   $9,370   $9,370 
Machinery and Equipment   10   $791,540   $512,450 
Furniture and Fixtures   5   $13,649   $13,649 
Computer Equipment   3   $11,824   $11,824 
Property and Equipment, gross       $826,383   $547,293 
Less Accumulated Depreciation       $(214,125)  $(127,178)
Property and Equipment       $612,258   $420,115 

 

Total depreciation expense was $89,526 for the nine months ended September 30, 2023.

 

In the nine months ended September 30, 2023, The Company purchased machinery worth $285,538. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $3,500 that originally was purchased for $6,448 and that had accumulated depreciation of $2,579, thereby taking a loss of $369 on the disposal of assets.

 

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
PATENTS
 9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
PATENTS

NOTE 5 – PATENTS

 

The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $247,854 as of September 30, 2023.

 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
DEBT

NOTE 6 – DEBT

 

Notes Payable – Related Parties

 

On August 10, 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $25,000, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants. It may convert into common stock at $0.13/share at the option of the holder for a total of 192,308 shares.

 

In June 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $50,000, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a 10% interest per annum. The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants.

 

In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $100,000, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $0.13/share for a total of 769,231 shares.

 

In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $150,000, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares.

 

In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $250,000, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $0.13/share for a total of 1,923,077 shares.

 

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. These amount are 1) Mark Koch $240,990 plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $579,942 out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, & Wellington Asset Holdings $1.5 million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.

 

On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $100,000 due and payable on May 1, 2018. The note does not accrue interest, however the Company provided 2,000,000 inducement shares to secure the note. These inducement shares were valued at $84,000. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $100,000 is to be paid out of future gross revenues to satisfy this note in full.

 

 

 

On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $50,000 due and payable on May 16, 2019. The note carried an interest rate of 5% plus the company issued 1,250,000 inducement shares to secure the note. These inducement shares were valued at $36,250. As of June 30, 2018 accrued interest on this note is $315. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $50,315.07 is to be paid out of future gross revenues.

 

Notes Payable – Other

 

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note had a principal balance of $96,570 and accrued interest at a rate of six percent (6%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019.

 

In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $143,000 due and payable on May 30, 2018. The note carried an 8% one-time interest charge, a $43,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $39,500. In May 2018, the company made two principal payments totaling $40,000. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company.

 

In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on September 21, 2018. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 40% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 500,000 inducement shares to secure the note. These inducement shares were valued at $14,500. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $100,000 out of 5% of the future gross revenue of the Company to settle both notes.

 

 

On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $32,000 to $20,000 payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.

 

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable  September 30, 2023   December 31, 2022 
Short Term Convertible Note – Related Party, including interest  $371,908   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment, incl interest  $276,944   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,386,984   $2,788,132 

 

Of the $3,386,984 payable as of September 30, 2023, $2,738,132 is due out of future revenue or future profits with no specific due date, and another $275,000 is due only after a significant capital investment. $2,417,502 of the $2,738,132 will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $969,482, consisting of $849,482 due to related parties, and $120,000 due to others.

 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS’ EQUITY
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY

 

The total number of shares of capital stock, which the Company has authority to issue, is 1,010 million, 1 billion of which are designated as common stock at $0.001 par value (the “Common Stock”) and 10 million of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of September 30, 2023, the Company had 302,750,963 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

 

For the nine months ended September 30, 2023, the Company issued an aggregate of 174,191 shares of its common stock for services valued at $29,300.

 

For the nine months ended September 30, 2023, 364,000 warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $48,447.

 

For the nine months ended September 30, 2023, 6,684,998 shares of common stock were issued for cash of $1,002,772.

 

For the nine months ended September 30, 2023, 5,950,148 warrants were exercised for proceeds of $97,250.

 

For the nine months ended September 30, 2023, 2,067,999 warrants expired.

 

For the nine months ended September 30, 2023, 7,050,000 unvested options expired and 125,000 vested options expired.

 

For the nine months ended September 30, 2023, 4,385,000 stock options vested. Using a Black-Scholes asset pricing model, these had a value of $637,028.

 

For the nine months ended September 30, 2023, 17,150,000 stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $2,835,613.

 

 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 8 - COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.

 

Cybersecurity

 

No material cybersecurity breach has occurred.

 

Leases

 

The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024. Annual rent commenced at $84,100 per annum and increased 3% per year. The latest amendment adjusted the lease to $102,950 per annum and increases at 3% per year. Tenant is also required to cover operating costs that are estimated at $3,600 per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General & Administrative expenses.

 

ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.

 

In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for 18.2 acres at an annual cost of $6,370 that the Company has the right to renew for a total of 5 years. A second lease began on March 31, 2023, for an additional 167.6 acres at a cost of $24,721 every 6 months that the Company also can continue for up to 5 years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.

 

Rent expense for the nine months ending September 30, 2023, and 2022, were $183,537 and $106,631, respectively.

 

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED  September 30, 2023   December 31, 2022 
Right of Use Lease Liabilities          
Current portion   101,905    95,172 
Long-term portion   8,793    85,983 
TOTAL   110,698    181,155 

 

As of September 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   24,715 
2024   85,983 
2025   0 
      
TOTAL  $110,698 

 

 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
RELATED PARTY TRANSACTIONS
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

 

Related Party Transactions

 

The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

 

  1) Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.
  2) A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they receive less than full salaries.

 

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

 
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:

 

From October 1, 2023, to the date of this filing, the Company issued 350,000 warrants for services. Using the Black-Scholes pricing model, these were valued at $29,991.

 

From October 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $15,000.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.

 
Principles of Consolidation

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.

 
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

 

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

 
Stock Compensation

Stock Compensation

 

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

 
Stock-based Compensation Valuation Methodology

Stock-based Compensation Valuation Methodology

 

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

 

The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23   7/26/23 
Risk-free interest rate   3.46%   3.77%   3.93%   3.86%
Expected life   5 years    7 years    5 years    10 years 
Expected dividends   0%   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%   87.22%
BIOF common stock fair value  $0.165   $0.170   $0.160   $0.160 

 
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 10 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

 
Patent Capitalization

Patent Capitalization

 

If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $247,854 as of September 30, 2023 and $222,109 as of December 31, 2022.

 
Research and Development

Research and Development

 

The Company expenses all research and development costs as incurred. For the nine months ended September 30, 2023, and September 30, 2022, the amounts charged to research and development expenses were $1,741,318 and $2,070,789, respectively.

 
Revenue Recognition

Revenue Recognition

 

The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:

 

  1. persuasive evidence of an arrangement exists;
  2. the product has been shipped or the services have been rendered to the customer;
  3. the sales price is fixed or determinable; and,
  4. collectability is reasonably assured.

 

 
Common Stock Purchase Warrants and Other Derivative Financial Instruments

Common Stock Purchase Warrants and Other Derivative Financial Instruments

 

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

 
Income Taxes

Income Taxes

 

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

 

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

 
Profit (Loss) per Common Share:

Profit (Loss) per Common Share:

 

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

 
Fair Value Measurements

Fair Value Measurements

 

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

 

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

 

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

 

Level 1 — quoted prices in active markets for identical assets or liabilities

 

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

 

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION

The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:

 

   2/10/23   2/14/23   3/1/23   3/31/23   4/5/23   4/11/23 
Risk-free interest rate   3.93%   3.77%   4.01%   3.60%   3.30%   3.54%
Expected life   5 years    10 years    10 years    5 years    10 years    5 years 
Expected dividends   0%   0%   0%   0%   0%   0%
Expected volatility   123.25%   123.26%   123.52%   120.71%   119.51%   119.39%
BIOF common stock fair value  $0.159   $0.159   $0.177   $0.166   $0.154   $0.145 

 

   4/26/23   6/5/23   7/13/23   7/26/23 
Risk-free interest rate   3.46%   3.77%   3.93%   3.86%
Expected life   5 years    7 years    5 years    10 years 
Expected dividends   0%   0%   0%   0%
Expected volatility   119.28%   103.20%   90.70%   87.22%
BIOF common stock fair value  $0.165   $0.170   $0.160   $0.160 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT (Tables)
 9 Months Ended
Sep. 30, 2023
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

 

PROPERTY AND EQUIPMENT  Life   September 30, 2023   December 31, 2022 
Building and Improvements   15   $9,370   $9,370 
Machinery and Equipment   10   $791,540   $512,450 
Furniture and Fixtures   5   $13,649   $13,649 
Computer Equipment   3   $11,824   $11,824 
Property and Equipment, gross       $826,383   $547,293 
Less Accumulated Depreciation       $(214,125)  $(127,178)
Property and Equipment       $612,258   $420,115 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
SCHEDULE OF NOTES PAYABLE

A summary of all debts indicated in the Notes above is as follows:

 

Notes Payable  September 30, 2023   December 31, 2022 
Short Term Convertible Note – Related Party, including interest  $371,908   $0 
Short Term Chapter 11 Settlement  $0   $50,000 
Long Term Notes Payable after capital investment, incl interest  $276,944   $0 
Long Term Notes Payable from future revenue — Related Party  $1,700,630   $1,700,630 
Long Term Notes Payable from future revenue — Other  $120,000   $120,000 
Long Term Note Payable from future profits — Related Party  $820,932   $820,932 
Long Term Note Payable from future profits — Other  $96,570   $96,570 
TOTAL NOTES  $3,386,984   $2,788,132 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Tables)
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET

The Company recognized the following related to leases in its Consolidated Balance Sheet:

 

PERIOD ENDED  September 30, 2023   December 31, 2022 
Right of Use Lease Liabilities          
Current portion   101,905    95,172 
Long-term portion   8,793    85,983 
TOTAL   110,698    181,155 
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS

As of September 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:

 

YEAR ENDED 

MINIMUM

DUE

 
2023   24,715 
2024   85,983 
2025   0 
      
TOTAL  $110,698 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
ORGANIZATION (Details Narrative)
 9 Months Ended
Sep. 30, 2023
Product Information [Line Items]  
Renewable fuel description This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.
Cost of Goods and Service, Product and Service Benchmark [Member] | Product Concentration Risk [Member] | Vertimass Technology [Member]  
Product Information [Line Items]  
Dscription of Production the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
GOING CONCERN (Details Narrative) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated losses $ 55,331,869 $ 52,781,586
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) - Warrant [Member]
 9 Months Ended
Sep. 30, 2023
$ / shares
Issuance Date 2/10/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.93%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 123.25%
BIOF common stock fair value $ 0.159
Issuance Date 2/14/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.77%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 123.26%
BIOF common stock fair value $ 0.159
Issuance Date 3/1/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 4.01%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 123.52%
BIOF common stock fair value $ 0.177
Issuance Date 3/31/2023 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.60%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 120.71%
BIOF common stock fair value $ 0.166
Issuance Date 4/5/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.30%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 119.51%
BIOF common stock fair value $ 0.154
Issuance Date 4/11/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.54%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 119.39%
BIOF common stock fair value $ 0.145
Issuance Date 4/26/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.46%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 119.28%
BIOF common stock fair value $ 0.165
Issuance Date 6/5/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.77%
Expected life 7 years
Expected dividends 0.00%
Expected volatility 103.20%
BIOF common stock fair value $ 0.170
Issuance Date 7/13/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.93%
Expected life 5 years
Expected dividends 0.00%
Expected volatility 90.70%
BIOF common stock fair value $ 0.160
Issuance Date 7/26/23 [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Risk-free interest rate 3.86%
Expected life 10 years
Expected dividends 0.00%
Expected volatility 87.22%
BIOF common stock fair value $ 0.160
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Patents $ 247,854   $ 247,854   $ 222,109
Research and development expenses $ 293,674 $ 404,157 $ 1,741,318 $ 2,070,789  
Minimum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life 5 years   5 years    
Maximum [Member]          
Property, Plant and Equipment [Line Items]          
Property and equipment, estimated useful life 10 years   10 years    
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 826,383 $ 547,293
Less Accumulated Depreciation (214,125) (127,178)
Property and Equipment 612,258 420,115
Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 9,370 9,370
Estimated Useful Lives 15 years  
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 791,540 512,450
Estimated Useful Lives 10 years  
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 13,649 13,649
Estimated Useful Lives 5 years  
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and Equipment, gross $ 11,824 $ 11,824
Estimated Useful Lives 3 years  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Depreciation $ 89,526  
Purchase value 826,383 $ 547,293
Pilot Plant [Member]    
Property, Plant and Equipment [Line Items]    
Purchase of machinery 285,538  
Machinery [Member]    
Property, Plant and Equipment [Line Items]    
Disposal of machinery 3,500  
Purchase value 6,448  
Accumulated depreciation 2,579  
Loss on disposal of assets $ 369  
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
PATENTS (Details Narrative) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Finite-Lived Patents, Gross $ 247,854 $ 222,109
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF NOTES PAYABLE (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Short Term Convertible Note – Related Party, including interest $ 371,908 $ 0
Short Term Chapter 11 Settlement 0 50,000
Long Term Notes Payable after capital investment, incl interest 276,944 0
Long Term Notes Payable from future revenue — Related Party 1,700,630 1,700,630
Long Term Notes Payable from future revenue — Other 120,000 120,000
Long Term Note Payable from future profits — Related Party 820,932 820,932
Long Term Note Payable from future profits — Other 96,570 96,570
TOTAL NOTES $ 3,386,984 $ 2,788,132
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
DEBT (Details Narrative)
 1 Months Ended
Aug. 10, 2023
USD ($)
shares
May 15, 2018
USD ($)
shares
Feb. 28, 2018
USD ($)
shares
Jul. 31, 2023
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
$ / shares
shares
Apr. 30, 2023
USD ($)
$ / shares
shares
Jan. 31, 2023
USD ($)
$ / shares
shares
May 31, 2018
USD ($)
Feb. 28, 2018
USD ($)
shares
Nov. 30, 2017
USD ($)
shares
Jul. 31, 2016
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Mar. 27, 2019
USD ($)
Mar. 26, 2019
USD ($)
Jun. 30, 2018
USD ($)
Debt Instrument [Line Items]                                
TOTAL NOTES                       $ 3,386,984 $ 2,788,132      
Notes payable, noncurrent                           $ 20,000 $ 32,000  
Due out of long term future revenue                       2,738,132        
Due related to long term notes payable capital investment                       275,000        
Notes payable amount to be discharged                       2,417,502        
Due to related parties                       969,482        
Notes Payable, Other Payables [Member] | AMG Energy Group [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount                     $ 96,570          
Debt interest rate                     6.00%          
Renegotiated notes, description                     The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019          
Renegotiated amount                     $ 96,570          
Business acquisition, percentage                     49.00%          
Edmund Burke [Member] | Convertible Debt [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount $ 50,000     $ 25,000   $ 150,000                    
Debt instrument, term           5 years                    
Warrant, reason for issuance, description       accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants   accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares                    
Edmund Burke [Member] | Convertible Debt [Member] | Common Stock [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares       192,308   1,153,846                    
Convertible, conversion price per share | $ / shares       $ 0.13   $ 0.13                    
Chris Kneppers [Member] | Convertible Debt One [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount         $ 50,000                      
Debt interest rate 10.00%       10.00%                      
Debt instrument, description The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants       The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants                      
Debt instrument, term 5 years       5 years                      
Chris Kneppers [Member] | Convertible Debt Two [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount         $ 100,000                      
Chris Kneppers [Member] | Convertible Debt Two [Member] | Common Stock [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares         769,231                      
Convertible, conversion price per share | $ / shares         $ 0.13                      
Chris Kneppers [Member] | Convertible Debt [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount             $ 250,000                  
Chris Kneppers [Member] | Convertible Debt [Member] | Common Stock [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares             1,923,077                  
Convertible, conversion price per share | $ / shares             $ 0.13                  
Chris Kneppers [Member] | Convertible Debt One [Member] | Warrant [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares 333,333       333,333                      
Related Party [Member]                                
Debt Instrument [Line Items]                                
Due to related parties                       849,482        
Related Party [Member] | AMG Energy Group [Member]                                
Debt Instrument [Line Items]                                
Debt interest rate                     6.00%          
Renegotiated notes, description                     The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019.          
Mark Koch [Member] | AMG Energy Group [Member]                                
Debt Instrument [Line Items]                                
Renegotiated amount                     $ 240,990          
Animated Family Films [Member] | AMG Energy Group [Member]                                
Debt Instrument [Line Items]                                
Renegotiated amount                     579,942          
Steven Dunkle CTWC Wellington Asset Holdings [Member] | AMG Energy Group [Member]                                
Debt Instrument [Line Items]                                
Renegotiated amount                     $ 1,500,000          
Steven Sadaka [Member] | Loans Payable [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount     $ 100,000           $ 100,000              
Debt instrument maturity date     May 01, 2018                          
Amount to be paid out of future gross revenues     $ 100,000                          
Steven Sadaka [Member] | Loans Payable [Member] | Inducement Shares [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares     2,000,000                          
Conversion of convertible securities, value     $ 84,000                          
Christopher Jemapete [Member] | Loans Payable [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount   $ 50,000                            
Debt interest rate   5.00%                            
Debt instrument maturity date   May 16, 2019                            
Amount to be paid out of future gross revenues   $ 50,315.07                            
Accrued interest, value                               $ 315
Christopher Jemapete [Member] | Loans Payable [Member] | Inducement Shares [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares   1,250,000                            
Conversion of convertible securities, value   $ 36,250                            
Pamela Jemapete [Member] | Loans Payable [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount   $ 50,000                            
Debt interest rate   5.00%                            
Debt instrument maturity date   May 16, 2019                            
Amount to be paid out of future gross revenues   $ 50,315.07                            
Accrued interest, value                               $ 315
Pamela Jemapete [Member] | Loans Payable [Member] | Inducement Shares [Member]                                
Debt Instrument [Line Items]                                
Shares, conversion of convertible securities | shares   1,250,000                            
Conversion of convertible securities, value   $ 36,250                            
Lucas Hoppel [Member] | Convertible Debt [Member]                                
Debt Instrument [Line Items]                                
Debt instrument principal amount     $ 165,000           $ 165,000 $ 143,000            
Debt interest rate     8.00%           8.00% 8.00%            
Shares, conversion of convertible securities | shares                 500,000 500,000            
Debt instrument maturity date                 Sep. 21, 2018 May 30, 2018            
Conversion of convertible securities, value                 $ 14,500 $ 39,500            
Original issue discount     $ 15,000           $ 15,000 $ 43,000            
Debt instrument conversion discount rate, percentage                 40 35            
Debt instrument principal payments               $ 40,000                
TOTAL NOTES     $ 100,000           $ 100,000 $ 100,000            
Percentage of future gross revenue                 5.00% 5.00%            
Other Related Party [Member]                                
Debt Instrument [Line Items]                                
Due to related parties                       $ 120,000        
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Dec. 31, 2022
Equity [Abstract]                
Capital units, authorized 1,010,000,000           1,010,000,000  
Common stock, shares authorized 1,000,000,000           1,000,000,000 1,000,000,000
Common stock, par value $ 0.001           $ 0.001 $ 0.001
Preferred stock, shares authorized 10,000,000           10,000,000 10,000,000
Preferred stock, par value $ 0.001           $ 0.001 $ 0.001
Common stock, shares issued 302,750,963           302,750,963 289,941,623
Common stock, shares outstanding 302,750,963           302,750,963 289,941,623
Preferred stock, shares Issued 0           0 0
Number of shares issued for services, shares             174,191  
Number of shares issued for services, value   $ 5,300 $ 24,000 $ 29,150 $ 16,150 $ 71,300 $ 29,300  
Warrants issued for services 50,000 314,000   37,333     364,000  
Warrants issued for services, value             $ 48,447  
Issuance of common stock and warrants for cash through PPM, shares             6,684,998  
Issuance of common stock and warrants for cash through PPM $ 325,000 $ 95,022 582,750 $ 340,000 $ 675,000   $ 1,002,772  
Warrants exercised share, shares             5,950,148  
Warrants exercised   $ 25,000 $ 72,250       $ 97,250  
Number of warrants expired             2,067,999  
Unvested options expired             7,050,000  
Unvested options expired             125,000  
Number of stock options vested, shares   2,000,000 2,385,000 825,000 800,000 10,560,000 4,385,000  
Number of stock options vested, value             $ 637,028  
Number of shares unvested 17,150,000           17,150,000  
Options issued and unvested value             $ 2,835,613  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
Current portion $ 101,905 $ 95,172
Long-term portion 8,793 85,983
TOTAL $ 110,698 $ 181,155
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)
Sep. 30, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
2023 $ 24,715
2024 85,983
2025 0
TOTAL $ 110,698
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Details Narrative)
 9 Months Ended
Sep. 01, 2020
USD ($)
a
Sep. 30, 2023
USD ($)
a
Sep. 30, 2022
USD ($)
Property, Plant and Equipment [Line Items]      
Annual rent   $ 84,100  
Percentage of increase in rent per year   3.00%  
Operating costs   $ 3,600  
Acres | a 18.2 167.6  
Lease cost $ 6,370 $ 24,721  
Lease renewal term 5 years 5 years  
Rent expense   $ 183,537 $ 106,631
Office and Laboratory Space [Member]      
Property, Plant and Equipment [Line Items]      
Lease extension period   This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024  
Percentage of increase in rent per year   3.00%  
Lease expense   $ 102,950  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 07, 2023
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Subsequent Event [Line Items]          
Warrants issued for services, shares   50,000 314,000 37,333 364,000
Warrants issued for services   $ 5,813 $ 42,634 $ 5,317  
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Warrants issued for services, shares 350,000        
Warrants issued for services $ 29,991        
Subsequent Event [Member] | Related Party [Member]          
Subsequent Event [Line Items]          
Convertible note $ 15,000        
XML 47 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001549145 2023-01-01 2023-09-30 0001549145 2023-11-10 0001549145 2023-09-30 0001549145 2022-12-31 0001549145 us-gaap:NonrelatedPartyMember 2023-09-30 0001549145 us-gaap:NonrelatedPartyMember 2022-12-31 0001549145 us-gaap:RelatedPartyMember 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-12-31 0001549145 2023-07-01 2023-09-30 0001549145 2022-07-01 2022-09-30 0001549145 2022-01-01 2022-09-30 0001549145 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001549145 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001549145 us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001549145 us-gaap:CommonStockMember 2022-12-31 0001549145 us-gaap:PreferredStockMember 2022-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001549145 us-gaap:RetainedEarningsMember 2022-12-31 0001549145 us-gaap:CommonStockMember 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-03-31 0001549145 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-06-30 0001549145 2023-06-30 0001549145 us-gaap:CommonStockMember 2021-12-31 0001549145 us-gaap:PreferredStockMember 2021-12-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001549145 us-gaap:RetainedEarningsMember 2021-12-31 0001549145 2021-12-31 0001549145 us-gaap:CommonStockMember 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-03-31 0001549145 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-06-30 0001549145 2022-06-30 0001549145 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001549145 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001549145 2023-01-01 2023-03-31 0001549145 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001549145 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001549145 2023-04-01 2023-06-30 0001549145 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001549145 us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001549145 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001549145 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001549145 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001549145 2022-01-01 2022-03-31 0001549145 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:PreferredStockMember 2022-04-01 2022-06-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001549145 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001549145 2022-04-01 2022-06-30 0001549145 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001549145 us-gaap:PreferredStockMember 2022-07-01 2022-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001549145 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001549145 us-gaap:CommonStockMember 2023-09-30 0001549145 us-gaap:PreferredStockMember 2023-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001549145 us-gaap:RetainedEarningsMember 2023-09-30 0001549145 us-gaap:CommonStockMember 2022-09-30 0001549145 us-gaap:PreferredStockMember 2022-09-30 0001549145 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001549145 us-gaap:RetainedEarningsMember 2022-09-30 0001549145 2022-09-30 0001549145 us-gaap:CostOfGoodsProductLineMember us-gaap:ProductConcentrationRiskMember BIOF:VertimassTechnologyMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryTenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateMarchOneTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilElevenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-01-01 2023-09-30 0001549145 BIOF:IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJuneFiveTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJulyThirteenTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 BIOF:IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember us-gaap:WarrantMember 2023-09-30 0001549145 srt:MinimumMember 2023-09-30 0001549145 srt:MaximumMember 2023-09-30 0001549145 us-gaap:BuildingImprovementsMember 2023-09-30 0001549145 us-gaap:BuildingImprovementsMember 2022-12-31 0001549145 us-gaap:MachineryAndEquipmentMember 2023-09-30 0001549145 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001549145 us-gaap:FurnitureAndFixturesMember 2023-09-30 0001549145 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001549145 us-gaap:ComputerEquipmentMember 2023-09-30 0001549145 us-gaap:ComputerEquipmentMember 2022-12-31 0001549145 BIOF:PilotPlantMember 2023-01-01 2023-09-30 0001549145 BIOF:MachineryMember 2023-01-01 2023-09-30 0001549145 BIOF:MachineryMember 2023-09-30 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember 2023-08-10 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-08-10 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-08-09 2023-08-10 0001549145 BIOF:ConvertibleDebtOneMember BIOF:ChrisKneppersMember us-gaap:WarrantMember 2023-08-09 2023-08-10 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember 2023-07-31 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember 2023-07-01 2023-07-31 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember us-gaap:CommonStockMember 2023-07-31 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember us-gaap:CommonStockMember 2023-07-01 2023-07-31 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtOneMember 2023-06-01 2023-06-30 0001549145 BIOF:ConvertibleDebtOneMember BIOF:ChrisKneppersMember us-gaap:WarrantMember 2023-06-01 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtTwoMember 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtTwoMember us-gaap:CommonStockMember 2023-06-30 0001549145 BIOF:ChrisKneppersMember BIOF:ConvertibleDebtTwoMember us-gaap:CommonStockMember 2023-06-01 2023-06-30 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember 2023-04-30 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember 2023-04-01 2023-04-30 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember us-gaap:CommonStockMember 2023-04-30 0001549145 us-gaap:ConvertibleDebtMember BIOF:EdmundBurkeMember us-gaap:CommonStockMember 2023-04-01 2023-04-30 0001549145 BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember 2023-01-31 0001549145 BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-31 0001549145 BIOF:ChrisKneppersMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2023-01-01 2023-01-31 0001549145 BIOF:AMGEnergyGroupMember us-gaap:RelatedPartyMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember us-gaap:RelatedPartyMember 2016-07-01 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember BIOF:MarkKochMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember BIOF:AnimatedFamilyFilmsMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember BIOF:StevenDunkleCTWCWellingtonAssetHoldingsMember 2016-07-31 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember 2018-02-28 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember 2018-02-28 2018-02-28 0001549145 BIOF:StevenSadakaMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-02-28 2018-02-28 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-05-15 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-05-15 2018-05-15 0001549145 BIOF:ChristopherJemapeteMember us-gaap:LoansPayableMember 2018-06-30 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-05-15 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember BIOF:InducementSharesMember 2018-05-15 2018-05-15 0001549145 BIOF:PamelaJemapeteMember us-gaap:LoansPayableMember 2018-06-30 0001549145 BIOF:AMGEnergyGroupMember us-gaap:NotesPayableOtherPayablesMember 2016-07-31 0001549145 BIOF:AMGEnergyGroupMember us-gaap:NotesPayableOtherPayablesMember 2016-07-01 2016-07-31 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2017-11-30 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2017-11-01 2017-11-30 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-05-01 2018-05-31 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-02-28 0001549145 BIOF:LucasHoppelMember us-gaap:ConvertibleDebtMember 2018-02-01 2018-02-28 0001549145 2019-03-26 0001549145 2019-03-27 0001549145 us-gaap:RelatedPartyMember 2023-09-30 0001549145 BIOF:OtherRelatedPartyMember 2023-09-30 0001549145 BIOF:OfficeAndLaboratorySpaceMember 2023-01-01 2023-09-30 0001549145 2020-09-01 0001549145 2020-09-01 2020-09-01 0001549145 us-gaap:SubsequentEventMember 2023-10-01 2023-11-07 0001549145 us-gaap:RelatedPartyMember us-gaap:SubsequentEventMember 2023-11-07 iso4217:USD shares iso4217:USD shares pure utr:acre false --12-31 Q3 false 0001549145 10-Q true 2023-09-30 2023 000-54942 BLUE BIOFUELS, INC. NV 45-4944960 3710 Buckeye Street Suite 120 Palm Beach Gardens FL 33410 (888) 607-3555 Common Stock par value $0.001 BIOF Yes Yes Non-accelerated Filer false true false 302750963 84663 211901 130835 38209 43119 253707 255020 214125 127178 612258 420115 30276 30276 105418 178399 247854 222109 995806 850899 1249513 1105919 698 37135 72670 72670 72670 72670 674594 307606 101905 95172 50000 350000 120124 76138 1319991 638721 8793 85983 2796562 2521562 216570 216570 3021925 2824115 4341916 3462836 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 1000000000 1000000000 302750963 302750963 289941623 289941623 302751 289942 51936716 50134727 -55331869 -52781586 -3092403 -2356917 -3092403 -2356917 1249513 1105919 219160 178512 943953 1223083 293674 404157 1741318 2070789 -369 -40099 512834 582669 2685640 3333971 -512834 -582669 -2685640 -3333971 206500 206500 23218 6711 63712 20135 2443 29313 7431 30934 180839 -36024 135357 -51069 -331995 -618693 -2550283 -3385040 -331995 -618693 -2550283 -3385040 -0.001 -0.002 -0.008 -0.012 -0.001 -0.002 -0.008 -0.012 302750963 302750963 277416282 277416282 302750963 302750963 277416282 277416282 289941623 289942 50134727 -52781586 -2356917 140000 140 23860 24000 3884998 3885 578865 582750 5450148 5450 66800 72250 2385000 391297 391297 -1064090 -1064090 299416769 299417 51195549 -53845676 -2350710 34194 34 5266 5300 2000000 245732 245732 633334 633 94389 95022 314000 42634 42634 500000 500 24500 25000 -1154199 -1154199 300584297 300584 51608069 -54999875 -3091221 50000 5813 5813 2166666 2167 322833 325000 -331995 -331995 302750963 302751 51936715 -55331870 -3092403 274003883 274004 47151353 -48821403 -1396046 447781 448 70852 71300 150000 150 7350 7500 10560000 1316277 1316277 -2040957 -2040957 274601664 274602 48545832 -50862360 -2041926 78600 79 16071 16150 200000 200 8200 8400 800000 99106 99106 4499999 4500 670500 675000 -725390 -725390 279380263 279380 49339710 -51587750 -1968660 279380263 279380 49339710 -51587750 -1968660 168842 169 28981 29150 825000 110922 110922 110922 110922 37333 5317 5317 5317 5317 2266665 2267 337733 340000 -618693 -618693 281815770 281817 49822662 -52206443 -2101964 281815770 281817 49822662 -52206443 -2101964 -2550283 -3385040 89526 102711 29300 116600 685474 1531622 -369 -40099 -4910 41729 130835 43986 20135 330551 62996 2525 -33647 -1494477 -1586253 282038 61800 25744 42501 -307782 -104301 97250 15900 625000 1002772 1015000 50000 1675022 1030900 -127237 -659653 211901 1164664 84663 505010 48447 5317 29300 116600 <p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5ii6rAhDwu3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – <span id="xdx_828_zOHLFGl9IU2i">ORGANIZATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Blue Biofuels, Inc (the “Company”) is a technology company focused on emerging technologies in renewable energy, biofuels, and lignin.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In early 2018, the Company’s chief executive officer (“CEO”) Ben Slager invented a new reactor technology with a higher yield and a continuous throughput in the Cellulose-to-Sugar process, or CTS, and the Company filed a process patent application for this technology. Mr. Slager has since further developed the system with the technical staff of the Company. The CTS patent was awarded in 2021 in the United States (U.S. Patent No. 10,994,255) and also in Japan and El Salvador. The Company also filed this patent in other major jurisdictions of the world including the European Patent Organization, Australia, Brazil, China, the African Regional Intellectual Property Organization, and the Russian Federation. The patent applications are currently pending in all of these international jurisdictions. In addition to this patent, the Company has received one additional patent (for which it has also applied in all the above-mentioned jurisdictions). Further, the company has filed for 4 other patents which are currently pending.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Slager has since further developed the system with the technical staff of the Company. The patented CTS process is a continuous mechanical/chemical dry process for breaking down cellulosic material for conversion into biofuels. CTS can break down any cellulosic material – including grasses and agricultural waste. The CTS mechanical/chemical process allows for exact process control to ensure that all the material passing through it does so on the optimum reaction parameters through which optimal efficiency is achieved.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The new technology made it worthwhile to financially restructure the Company through Chapter 11. The Company voluntarily filed for Chapter 11 on October 22, 2018, in the U.S. Bankruptcy Court in the Southern District of Florida. The Company exited Chapter 11 on September 18, 2019, while keeping all classes, including shareholders, unimpaired. The bankruptcy case was closed on October 25, 2019.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">CTS is environmentally friendly in that it recycles the water and catalyst, and it has a low carbon footprint: the amount of added atmospheric carbon created by burning the biofuels produced by the CTS system was absorbed by the plant-based feedstock while growing and is merely released back into the atmosphere. No extra CO2 is released into the atmosphere when our biofuels are burned. This is to be distinguished from fossil fuels because new CO2 is released when fossil fuels are burned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes a significant difference between CTS cellulosic ethanol and corn ethanol is the wide range of abundantly available feedstocks that CTS can process compared to just corn as the feedstock. The CTS feedstocks are nonfood and have much lower costs than corn. In addition, while in corn ethanol only the corn kernels are used, CTS uses the whole plant or its waste products, meaning it could obtain much higher yields per acre.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2022, the Company partnered with K.R. Komarek to build its CTS machines going forward. Komarek is an industry leading manufacturing company that builds briquetting machines and compaction/granulation systems with throughput capacities up to 50 tons per hour.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, the Company completed the build-out of a pilot plant based on a modified Komarek machine and is in the process of further testing and optimizing the plant. The Company believes that it can optimize the pre and post processing elements at this pilot scale plant to finalize design and operational parameters to provide operating cost estimates of a full-scale commercial volume system. Due to its mechanical nature and modularity, we anticipate that one plant would have multiple modular CTS systems.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company has licensed the Vertimass Process to convert ethanol into sustainable aviation fuel (SAF) and other renewable biofuels including bio-gasoline. The license agreement with Vertimass is the subject to a confidentiality agreement between the parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Plan of Operation</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total process from cellulosic feedstock to SAF consists basically of three steps:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conversion from feedstock to fermentable cellulosic sugars (CTS)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ferment the cellulosic sugars into cellulosic ethanol.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covert the ethanol into SAF and related products. This third step happens with the Vertimass technology which the Company has licensed.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the fact that the Vertimass technology is mature and ready for production, <span id="xdx_900_eus-gaap--ConcentrationRiskProduct_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--CostOfGoodsProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__dei--LegalEntityAxis__custom--VertimassTechnologyMember_zkQII6W4Fhn3" title="Dscription of Production">the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits</span>. Commencing commercial production will require project financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any new biofuels plant that is built would require various government permits. In particular, renewable fuels are subject to rigorous testing and premarket approval requirements by the EPA’s Office of Transportation and Air Quality and regulatory authorities in other countries. In the U.S., various federal, and, in some cases, state statutes and regulations also govern or impact the manufacturing, safety, storage and use of renewable fuels. The process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations requires the expenditure of resources. The Company anticipates raising the necessary capital for this as a part of its project-based financing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ethanol industry is competitive with over 200 ethanol plants in the United States alone. Currently, the vast majority use corn as feedstock. Their profitability depends highly on the fluctuations between the price of corn and the price of ethanol. Since the Company does not plan to use corn, and plans on having long-term purchase agreements with cellulosic feedstock suppliers, we anticipate that our profitability will be more consistent. Further, cellulosic biofuels yield much higher incentives than non-cellulosic biofuels.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Energy Policy Act of 2005, which included the Renewable Fuel Standard Program enforced by the US Environmental Protection Agency (EPA), mandates a certain amount of renewable fuel be blended into the transportation fuel used by all vehicles in the country. <span id="xdx_909_ecustom--RenewableFuelDescription_c20230101__20230930_zXQUcBOA0QQk" title="Renewable fuel description">This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 45Z of the Inflation Reduction Act passed on August 16, 2022, offers a Clean Fuel Production Credit (CFPC) per gallon of transportation fuel produced with a base amount of 20 cents per gallon or up to $1 per gallon for a qualified facility (depending on its carbon index) that was built while paying at least prevailing wages and which met apprenticeship requirements. For sustainable aviation fuel, those figures are 35 cents and $1.75 per gallon respectively. The Company plans to apply for CFPC credits when it begins building its commercial facilities. The CFPC currently does not apply to transportation fuel sold after December 31, 2027.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Low Carbon Fuel Standard Credit (LCFS) is offered by various states (primarily California) for any amount of reduced CO2 in the production lifecycle of transportation fuels as compared to the amount of CO2 emitted in the production lifecycle of fossil fuels. The production lifecycle includes transportation costs to the point of use. California is currently offering around $67.00 per metric ton of CO2 reduction. When it is closer to commercial production, the Company plans to analyze the cost effectiveness of applying for these LCFS credits to determine in which state it could earn the most credits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At commercial scale, management expects to be able to earn substantial renewable fuel credits and produce sustainable ethanol, sustainable aviation fuel, and other sustainable biofuels more profitably than they could be from existing commercial corn ethanol producers. Cellulosic ethanol comes with a much more valuable D3 RIN credit as compared to the D6 RIN allocated to corn ethanol; cellulosic SAF comes with a very valuable D7 RIN, and cellulosic bio-gasoline comes with a valuable D3 RIN. The Company also expects to receive Clean Fuel Production Credits related to section 45Z of the Inflation Reduction Act, whereas these credits are so far not available for corn ethanol producers; and the Company also plans to pursue Low Carbon Fuel Standard Credits.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After its first plant is profitable, the Company intends to grow with additional plants in the United States and explore international growth by either licensing the CTS technology or forming joint ventures with foreign domestic partners to build plants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its management and consultants have significant experience in the development of technologies from concept to commercialization. As of this date, the Company has not generated any material revenues from its business.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> the Company is reviewing whether to start executing on SAF production on a 10 million gallon per year level, and then add the first two steps on to it in a later phase when CTS is fully commercialized. The Company intends to build commercial CTS and ethanol facilities on the front-end to produce cellulosic SAF and generate the large D7 RIN and other government credits This Program provides monetary incentives to companies that produce renewable transportation fuel, and establishes Renewable Identification Numbers (RINs) or credits for each gallon of renewable transportation fuel produced in the United States, and breaks down those fuels into different D-codes depending on the source of the renewable fuel. D3 is the code for renewable ethanol that comes from cellulosic materials. The EPA’s final D3 RIN volume mandates for cellulosic biofuel include 840 million gallons for 2023, 1.09 billion gallons for 2024, and 1.38 billion gallons for 2025 (the D3 mandate). This mandate has increased every year and is statutorily mandated to increase in the future and become a larger portion of the full renewable fuels mandate, if and when cellulosic biofuels can be produced profitably in larger and larger quantities. The RFS mandate for 2023 calls for 20.94 billion gallons of total renewable fuel, 15 billion from conventional biofuels (corn ethanol) and 5.94 billion from advanced biofuels, including cellulosic biofuels. The “blend wall” (or upper limit to the amount of ethanol that can be blended into U.S. gasoline and automobile performance and comply with the Clean Air Act) of limiting ethanol content in gasoline to 10%, limits the total amount of ethanol consumed in the United States. Recent proposals have make 15% blending available year around in some states. The value of the D3 RIN fluctuates, but as of this filing, it is approximately $3.53 per gallon of ethanol. For comparison, the D6 RIN for corn ethanol is $0.79. To profit from these incentives, the Company plans to apply for these D3 RIN credits as it brings its first plant into commercial operation. <p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zKNv51KQvj5c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 – <span id="xdx_82B_z5MHzopaSSci">GOING CONCERN</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any significant revenue since inception and has incurred losses since inception. As of September 30, 2023, the Company has incurred accumulated losses of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20230930_z9GqJ6ZBx8T4" title="Accumulated losses">55,331,869</span>. The Company expects to incur significant additional losses and liabilities in connection with its start-up and commercialization activities. These factors, among others, raise substantial doubt as to the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities, and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, or sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The COVID-19 pandemic has negatively affected the U.S. and global economies, disrupted global supply chains, resulted in significant travel and transport restrictions, including mandated closures and orders to “shelter-in-place,” and created significant disruption of the financial markets. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business, including how it will impact our supply chain, employees, and potential future customers. Our office and lab have remained open during the pandemic. Nevertheless, the pandemic slowed our ability to commercialize our process in two ways: by adversely affecting our ability to raise capital, and by adversely affecting the supply chain of laboratory equipment and various parts of upgrades to our CTS system, which slowed the development of our prototypes. Supply chain issues also delayed the delivery of various parts of our pilot plant. The extent to which our operations may be further impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted. We may experience additional operating costs due to increased challenges with our workforce (including as a result of illness, absenteeism or government orders), access to supplies, capital, and fundamental support services (such as shipping and transportation). Even after the COVID-19 pandemic has subsided, we may experience materially adverse impacts to our business due to any resulting economic recession or depression. Furthermore, the effects of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> -55331869 <p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zHxK1lHsrtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – <span id="xdx_826_zIGQxcjZa9Mj">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzC1OnRXnSCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_869_zzJWN3saVXR7">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zggGtVDPyDc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zX3ZyXvlFMAj">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--UseOfEstimates_zfsSKGNBvPS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zy8IWss48AQ">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6GOXDI6Dyuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_zlkOXDLjICt5">Cash and Cash Equivalents</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3KK2UcoLcJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_z8bZs5VXxgoc">Stock Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_znyved0r7EY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zYnGfQ1jycJk">Stock-based Compensation Valuation Methodology</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zvTp1nP5iBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zkrM1SEyAnI7" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/10/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/14/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/1/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/31/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/11/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeXgbLvyJNi" style="width: 6%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRQGvbebm8b" style="width: 6%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5dKPleQP38d" style="width: 6%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzXwpONjpgm" style="width: 6%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu78vnkrY4ai" style="width: 6%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjM3Ew3gIUDc" style="width: 6%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLYN6sgObYe5" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IuRzgtgj7d" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCWo5SnDNN3" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHIGfi14ULi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lU1eTc7Sh5" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmFXDp3ebmgb" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zueGbc3m6eKf" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcZ9Ql2UVDM6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgQEqYLB1csa" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQF0rX109GVk" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4q6GqlmBHLg" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rBShRboZWi" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzv5np4qGTY9" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzZLUOBDDIqb" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVhbRe66fvh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyiHnZGNKQK2" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8oeJ1FkDt4" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziMc7sMGQfoa" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziD3Tt0rDlP4" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhxKOHOzl7Mc" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCE8oY1UByE1" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlyclfftZe8h" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZon6yMNtKZ4" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrEBskwBuf7" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/13/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBnny9GSZjle" style="width: 11%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdtIX8jyi8R8" style="width: 11%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHZ17u80h4Gb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKsLWG9iEfqb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.86</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziN1FEgGEJNi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD7Qp3xcpQ1k" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaP2cASP5uIi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2eTmnsoF7O9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztJtm9WK5Jp8" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3H91oZ9Ymu3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4ec3C3Bk4U" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZUHn22JHsqh" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkbT7Xl5hh4g" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTMNcpJ9ITd1" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zafmxZzkn7Dd" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ6t2fvqCNKk" style="text-align: right" title="Expected volatility">87.22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHVQNhSKGwA2" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxnmqfT7AEa2" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbFEbNYROA5h" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYKC6chCAtd" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zhIFYhkR9Kjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZbmicwEMuaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_z5BJ3nlfHsE">Property and Equipment</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zlgQkXptYtwk" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zW2XZC9ovtNe" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zaMpLXIJwkye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zVJ34z3Umaqc">Patent Capitalization</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20230930_zKX25ErW8Og" title="Patents">247,854</span> as of September 30, 2023 and $<span id="xdx_90B_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20221231_z5btvFtw59hl" title="Patents">222,109</span> as of December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zKbx15UfNOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86B_zuSmxVUDHlPc">Research and Development</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses all research and development costs as incurred. For the nine months ended September 30, 2023, and September 30, 2022, the amounts charged to research and development expenses were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930_zzvi5gm0P981" title="Research and development expenses">1,741,318</span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220930_zmeeHNT4ELtc" title="Research and development expenses">2,070,789</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKVIJrIPd90h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zPl42LUauQG9">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">persuasive evidence of an arrangement exists;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the product has been shipped or the services have been rendered to the customer;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the sales price is fixed or determinable; and,</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">collectability is reasonably assured.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_ztwUTT6xCyJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zPw1qL0asPS7">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLyA8j4166y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zn77nKz6L137">Impairment of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zpFhNoPhfMN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zY4H6UYPTjp1">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zMBBDUNc3TDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zunmOLgb6zE4">Profit (Loss) per Common Share:</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWTjBaDR4eOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zkIdUvcG7cji">Fair Value Measurements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 — quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zGPyJqPSI7Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zCE6KBc1llqc">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</p> <p id="xdx_856_z4tiatRpAg8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zzC1OnRXnSCk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_869_zzJWN3saVXR7">Basis of Presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zggGtVDPyDc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86D_zX3ZyXvlFMAj">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. All material intercompany transactions and balances were eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--UseOfEstimates_zfsSKGNBvPS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zy8IWss48AQ">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> </p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z6GOXDI6Dyuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_zlkOXDLjICt5">Cash and Cash Equivalents</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_849_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3KK2UcoLcJg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_863_z8bZs5VXxgoc">Stock Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--StockbasedCompensationValuationMethodologyPolicyTextBlock_znyved0r7EY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zYnGfQ1jycJk">Stock-based Compensation Valuation Methodology</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zvTp1nP5iBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zkrM1SEyAnI7" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/10/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/14/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/1/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/31/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/11/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeXgbLvyJNi" style="width: 6%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRQGvbebm8b" style="width: 6%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5dKPleQP38d" style="width: 6%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzXwpONjpgm" style="width: 6%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu78vnkrY4ai" style="width: 6%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjM3Ew3gIUDc" style="width: 6%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLYN6sgObYe5" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IuRzgtgj7d" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCWo5SnDNN3" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHIGfi14ULi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lU1eTc7Sh5" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmFXDp3ebmgb" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zueGbc3m6eKf" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcZ9Ql2UVDM6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgQEqYLB1csa" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQF0rX109GVk" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4q6GqlmBHLg" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rBShRboZWi" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzv5np4qGTY9" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzZLUOBDDIqb" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVhbRe66fvh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyiHnZGNKQK2" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8oeJ1FkDt4" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziMc7sMGQfoa" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziD3Tt0rDlP4" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhxKOHOzl7Mc" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCE8oY1UByE1" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlyclfftZe8h" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZon6yMNtKZ4" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrEBskwBuf7" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/13/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBnny9GSZjle" style="width: 11%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdtIX8jyi8R8" style="width: 11%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHZ17u80h4Gb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKsLWG9iEfqb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.86</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziN1FEgGEJNi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD7Qp3xcpQ1k" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaP2cASP5uIi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2eTmnsoF7O9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztJtm9WK5Jp8" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3H91oZ9Ymu3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4ec3C3Bk4U" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZUHn22JHsqh" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkbT7Xl5hh4g" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTMNcpJ9ITd1" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zafmxZzkn7Dd" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ6t2fvqCNKk" style="text-align: right" title="Expected volatility">87.22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHVQNhSKGwA2" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxnmqfT7AEa2" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbFEbNYROA5h" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYKC6chCAtd" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_zhIFYhkR9Kjc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zvTp1nP5iBui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock compensation issued for services during the nine months ended September 30, 2023, were valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the nine months ended September 30, 2023:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zkrM1SEyAnI7" style="display: none">SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/10/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2/14/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/1/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3/31/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/11/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zGeXgbLvyJNi" style="width: 6%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXRQGvbebm8b" style="width: 6%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5dKPleQP38d" style="width: 6%; text-align: right" title="Risk-free interest rate">4.01</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzXwpONjpgm" style="width: 6%; text-align: right" title="Risk-free interest rate">3.60</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zu78vnkrY4ai" style="width: 6%; text-align: right" title="Risk-free interest rate">3.30</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjM3Ew3gIUDc" style="width: 6%; text-align: right" title="Risk-free interest rate">3.54</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLYN6sgObYe5" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3IuRzgtgj7d" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBCWo5SnDNN3" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQHIGfi14ULi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lU1eTc7Sh5" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmFXDp3ebmgb" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zueGbc3m6eKf" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcZ9Ql2UVDM6" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgQEqYLB1csa" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQF0rX109GVk" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4q6GqlmBHLg" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5rBShRboZWi" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzv5np4qGTY9" style="text-align: right" title="Expected volatility">123.25</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzZLUOBDDIqb" style="text-align: right" title="Expected volatility">123.26</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYVhbRe66fvh" style="text-align: right" title="Expected volatility">123.52</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zyiHnZGNKQK2" style="text-align: right" title="Expected volatility">120.71</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8oeJ1FkDt4" style="text-align: right" title="Expected volatility">119.51</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziMc7sMGQfoa" style="text-align: right" title="Expected volatility">119.39</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryTenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziD3Tt0rDlP4" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhxKOHOzl7Mc" style="text-align: right" title="BIOF common stock fair value">0.159</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchOneTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCE8oY1UByE1" style="text-align: right" title="BIOF common stock fair value">0.177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlyclfftZe8h" style="text-align: right" title="BIOF common stock fair value">0.166</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZon6yMNtKZ4" style="text-align: right" title="BIOF common stock fair value">0.154</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilElevenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdrEBskwBuf7" style="text-align: right" title="BIOF common stock fair value">0.145</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6/5/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/13/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7/26/23</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBnny9GSZjle" style="width: 11%; text-align: right" title="Risk-free interest rate">3.46</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdtIX8jyi8R8" style="width: 11%; text-align: right" title="Risk-free interest rate">3.77</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHZ17u80h4Gb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.93</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKsLWG9iEfqb" style="width: 11%; text-align: right" title="Risk-free interest rate">3.86</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziN1FEgGEJNi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zD7Qp3xcpQ1k" title="Expected life">7</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaP2cASP5uIi" title="Expected life">5</span> years</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2eTmnsoF7O9" title="Expected life">10</span> years</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Expected dividends</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztJtm9WK5Jp8" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3H91oZ9Ymu3" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4ec3C3Bk4U" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZUHn22JHsqh" style="text-align: right" title="Expected dividends">0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkbT7Xl5hh4g" style="text-align: right" title="Expected volatility">119.28</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zTMNcpJ9ITd1" style="text-align: right" title="Expected volatility">103.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zafmxZzkn7Dd" style="text-align: right" title="Expected volatility">90.70</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20230101__20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQ6t2fvqCNKk" style="text-align: right" title="Expected volatility">87.22</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">BIOF common stock fair value</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHVQNhSKGwA2" style="text-align: right" title="BIOF common stock fair value">0.165</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJuneFiveTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxnmqfT7AEa2" style="text-align: right" title="BIOF common stock fair value">0.170</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyThirteenTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbFEbNYROA5h" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--SharePrice_iI_c20230930__us-gaap--AwardDateAxis__custom--IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVYKC6chCAtd" style="text-align: right" title="BIOF common stock fair value">0.160</td><td style="text-align: left"> </td></tr> </table> 0.0393 0.0377 0.0401 0.0360 0.0330 0.0354 P5Y P10Y P10Y P5Y P10Y P5Y 0 0 0 0 0 0 1.2325 1.2326 1.2352 1.2071 1.1951 1.1939 0.159 0.159 0.177 0.166 0.154 0.145 0.0346 0.0377 0.0393 0.0386 P5Y P7Y P5Y P10Y 0 0 0 0 1.1928 1.0320 0.9070 0.8722 0.165 0.170 0.160 0.160 <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zZbmicwEMuaj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_z5BJ3nlfHsE">Property and Equipment</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MinimumMember_zlgQkXptYtwk" title="Property and equipment, estimated useful life">5</span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__srt--RangeAxis__srt--MaximumMember_zW2XZC9ovtNe" title="Property and equipment, estimated useful life">10</span> years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> P5Y P10Y <p id="xdx_84B_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zaMpLXIJwkye" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zVJ34z3Umaqc">Patent Capitalization</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product is currently under research and development and is not currently approved for market, costs incurred in connection with patent applications should generally be expensed in the income statement because there is uncertainty as to the future economic benefit of the asset. Conversely, if a product is approved for market (as is the case of the end product ethanol of the CTS process), or if future economic benefit is probable, or if an alternative future use is available to the Company, then such patent costs can be capitalized and amortized over the expected life of the patent(s). Since the Company’s primary end product is sugar converting to ethanol, which are in wide use, the Company has determined that it is reasonable to capitalize the patent costs associated with its CTS process, which were $<span id="xdx_90C_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20230930_zKX25ErW8Og" title="Patents">247,854</span> as of September 30, 2023 and $<span id="xdx_90B_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20221231_z5btvFtw59hl" title="Patents">222,109</span> as of December 31, 2022.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 247854 222109 <p id="xdx_84B_eus-gaap--ResearchAndDevelopmentExpensePolicy_zKbx15UfNOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86B_zuSmxVUDHlPc">Research and Development</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses all research and development costs as incurred. For the nine months ended September 30, 2023, and September 30, 2022, the amounts charged to research and development expenses were $<span id="xdx_905_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20230101__20230930_zzvi5gm0P981" title="Research and development expenses">1,741,318</span> and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20220101__20220930_zmeeHNT4ELtc" title="Research and development expenses">2,070,789</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 1741318 2070789 <p id="xdx_849_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zKVIJrIPd90h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86A_zPl42LUauQG9">Revenue Recognition</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows FASB ASC 606 “Revenue Recognition” and recognizes revenue when it is realized or realizable and earned. The Company’s revenues will be derived principally from joint ventures, royalties and eventually corporate owned plants. However, no sales have occurred through those revenue streams to date. The Company considers revenue realized or realizable and earned when all of the following criteria are met:</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-size: 10pt"> </span></td> <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">persuasive evidence of an arrangement exists;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the product has been shipped or the services have been rendered to the customer;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">3.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">the sales price is fixed or determinable; and,</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"> </span></td> <td style="text-align: justify"><span style="font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">collectability is reasonably assured.</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_ecustom--CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock_ztwUTT6xCyJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_86C_zPw1qL0asPS7">Common Stock Purchase Warrants and Other Derivative Financial Instruments</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zLyA8j4166y9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zn77nKz6L137">Impairment of Long-Lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--IncomeTaxPolicyTextBlock_zpFhNoPhfMN3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zY4H6UYPTjp1">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zMBBDUNc3TDk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zunmOLgb6zE4">Profit (Loss) per Common Share:</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zWTjBaDR4eOf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zkIdUvcG7cji">Fair Value Measurements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 — quoted prices in active markets for identical assets or liabilities</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zGPyJqPSI7Sk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zCE6KBc1llqc">Recent Accounting Pronouncements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.</p> <p id="xdx_808_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z6NqnL41fux1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – <span><span id="xdx_82D_zVmxP2krsE3f">PROPERTY AND EQUIPMENT</span></span></b></p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zPVooHD8L6Xl" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zo02PtwbM2Sf" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PROPERTY AND EQUIPMENT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230930_zoPXOLTpbUP1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zG4SX8nZCbC1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zqvX30FlTTGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Building and Improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 8%; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zdqH4cndC5N6" title="Estimated Useful Lives">15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zW7IU8dI4boj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and Equipment</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmwiO2YKmY53" title="Estimated Useful Lives">10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">791,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">512,450</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z3dGydktkmqd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and Fixtures</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zorIUGGYWljc" title="Estimated Useful Lives">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3C7t8KX7eea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Computer Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zohlnEH5uxzj" title="Estimated Useful Lives">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz0SA_z3xqu5cKZbOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, gross</span></td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">826,383</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">547,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpM5_msPPAENz0SA_zufBtIGMcoZf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(214,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz0SA_zrWLdQPHJ1K7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">612,258</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z7GrtQQFzMKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total depreciation expense was $<span id="xdx_906_eus-gaap--Depreciation_c20230101__20230930_zQHrBmGLPXm3" title="Depreciation">89,526</span> for the nine months ended September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the nine months ended September 30, 2023, The Company purchased machinery worth $<span id="xdx_90F_eus-gaap--PaymentsToAcquireMachineryAndEquipment_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PilotPlantMember_z2WnPGHIZ7Ul" title="Purchase of machinery">285,538</span>. This was primarily related to the pilot plant. The Company disposed of machinery that was no longer in use for a total of $<span id="xdx_90B_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_zBvkAEsFGlJd" title="Disposal of machinery">3,500</span> that originally was purchased for $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_zWLMbcm9lJF" title="Purchase value">6,448</span> and that had accumulated depreciation of $<span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentOtherAccumulatedDepreciation_iI_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_ziHGgqWgT6v4" title="Accumulated depreciation">2,579</span>, thereby taking a loss of $<span id="xdx_903_eus-gaap--GainLossOnSaleOfPropertyPlantEquipment_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryMember_ziANXsz4QzM6" title="Loss on disposal of assets">369</span> on the disposal of assets.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p id="xdx_894_eus-gaap--PropertyPlantAndEquipmentTextBlock_zPVooHD8L6Xl" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BF_zo02PtwbM2Sf" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PROPERTY AND EQUIPMENT</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Life</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230930_zoPXOLTpbUP1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zG4SX8nZCbC1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zqvX30FlTTGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 58%; text-align: left">Building and Improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 8%; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingImprovementsMember_zdqH4cndC5N6" title="Estimated Useful Lives">15</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">9,370</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zW7IU8dI4boj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Machinery and Equipment</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zmwiO2YKmY53" title="Estimated Useful Lives">10</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">791,540</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">512,450</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z3dGydktkmqd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Furniture and Fixtures</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zorIUGGYWljc" title="Estimated Useful Lives">5</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">13,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z3C7t8KX7eea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Computer Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zohlnEH5uxzj" title="Estimated Useful Lives">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,824</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENz0SA_z3xqu5cKZbOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 12pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, gross</span></td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">826,383</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">547,293</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzpM5_msPPAENz0SA_zufBtIGMcoZf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less Accumulated Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(214,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(127,178</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENz0SA_zrWLdQPHJ1K7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Property and Equipment</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">612,258</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">420,115</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> P15Y 9370 9370 P10Y 791540 512450 P5Y 13649 13649 P3Y 11824 11824 826383 547293 214125 127178 612258 420115 89526 285538 3500 6448 2579 369 <p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zZYjNlPS5y8l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – <span><span id="xdx_82D_zFktAtQkcDIe">PATENTS</span></span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has been granted one patent on its technology and one continuation patent, has filed for three others that are pending, and has also applied for international patents. The Company has capitalized the legal and filing fees in the amount of $<span id="xdx_904_eus-gaap--FiniteLivedPatentsGross_iI_c20230930_zUowUXRokjBh" title="Finite-Lived Patents, Gross">247,854</span> as of September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 247854 <p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zD3TYfCT4bwh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – <span id="xdx_829_zlAXdMKMVzO">DEBT</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Notes Payable – Related Parties</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 10, 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230810__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zeGuqgrxwJze" title="Principal balance">50,000</span>, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230810__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_z9w1PPFQosEh" title="Debt instrument, interest rate">10</span>% interest per annum. <span id="xdx_905_eus-gaap--DebtInstrumentDescription_c20230809__20230810__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zoPeptxrtSdc" title="Debt instrument, description">The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a <span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20230809__20230810__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zsWVtUy7Yst8" title="Debt instrument, term">5</span>-year expiration, for a total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230809__20230810__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebtOneMember_zq95kwpy8Uh1" title="Conversion of convertible securities, shares">333,333</span> shares and warrants</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_c20230731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zI7EvP7Y7Iw3" title="Principal balance">25,000</span>, that is to be repaid when the Company receives an equity investment of at least $3 million. Otherwise, it <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20230701__20230731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zefzPowRS4C8" title="Warrant, reason for issuance, description">accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants</span>. It may convert into common stock at $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zFrI2YBxBRXa" title="Convertible, conversion price per share">0.13</span>/share at the option of the holder for a total of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230701__20230731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zpQI1qpMWpG" title="Conversion of convertible securities, shares">192,308</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company entered into a long-term convertible note with board member Chris Kneppers, with a principal balance of $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zJb509S1fks1" title="Principal balance">50,000</span>, that is to be repaid when the Company receives $5 million in equity investment. The Note carries a <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zhZtUdfwlEHh" title="Debt instrument, interest rate">10</span>% interest per annum. <span id="xdx_908_eus-gaap--DebtInstrumentDescription_c20230601__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_zUOJn7agt2hi" title="Debt instrument, description">The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20230601__20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtOneMember_znjQVbrP4Dr8" title="Debt instrument, term">5</span>-year expiration, for a total of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230601__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebtOneMember_zdO1DN4RfJ0h" title="Conversion of convertible securities, shares">333,333</span> shares and warrants</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember_zRsGWx41Vs84" title="Principal balance">100,000</span>, that if it’s not paid by December 6, 2023, it automatically extends for another 6 months. It’s convertible at the option of the lender into common stock at $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember_zpXUJsNWfYQd" title="Convertible, conversion price per share">0.13</span>/share for a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230601__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertibleDebtTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember_zUT3o5xfP5Yl" title="Conversion of convertible securities, shares">769,231</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2023, the Company entered into a long-term convertible note with board member Edmund Burke, with a principal balance of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_c20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbrKuicpDFSf" title="Principal balance">150,000</span>, that is to be repaid when the Company receives an equity investment of at least $1.5 million. Otherwise, it <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20230401__20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ztC2RrODEhCa" title="Warrant, reason for issuance, description">accrued warrants, with a strike price of 15 cents and an expiration of <span id="xdx_900_eus-gaap--DebtInstrumentTerm_dtY_c20230401__20230430__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z702q2KnFeOl" title="Debt instrument, term">5</span> years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zgafjEViYfzi" title="Convertible, conversion price per share">0.13</span>/share at the option of the holder for a total of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230401__20230430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--EdmundBurkeMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zTQD0MXQ4IVi" title="Conversion of convertible securities, shares">1,153,846</span> shares</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2023, the Company entered into a short-term convertible note with board member Chris Kneppers, with a principal balance of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20230131__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZxBSq0QljDe" title="Principal balance">250,000</span>, that if it’s not paid by July 4, 2023, it converts at the option of the Company into common stock at $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zIMHvfMLFLZe" title="Convertible, conversion price per share">0.13</span>/share for a total of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20230101__20230131__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChrisKneppersMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zxvQ876qL9Jj" title="Shares, conversion of convertible securities">1,923,077</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes had a value of $2,002,126 and accrued interest at a rate of six percent (<span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20160731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember_zYUAl0zBXENg" title="Interest rate">6</span>%) per annum. As of December 31, 2018, the total interest accrued on the notes was $278,794.68. The notes were held by related parties with the understanding that the notes were not to be paid until the Company begins generating profit. The Company renegotiated some of these notes during its Chapter 11 proceedings, whereas others failed to submit a claim and were discharged upon the Court’s Confirmation Order approving the Company’s Chapter 11 Plan on September 18, 2019. <span id="xdx_901_ecustom--RenegotiatedNotesDescription_c20160701__20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z8CkvlKMQ26h" title="Renegotiated notes description">The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019.</span> These amount are 1) Mark Koch $<span id="xdx_90D_ecustom--RenegotiatedAmount_iI_c20160731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MarkKochMember__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember_zxdrlFziszAi" title="Renegotiated amount">240,990</span> plus 6% interest on any portion not repaid within 12 months of the Company’s first reported quarterly net profit; 2) Animated Family Films $<span id="xdx_908_ecustom--RenegotiatedAmount_iI_c20160731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AnimatedFamilyFilmsMember__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember_zoktBKl2kpGg" title="Renegotiated amount">579,942</span> out of the Company’s net profits plus 6% interest; 3) Steven Dunkle, CTWC, &amp; Wellington Asset Holdings $<span id="xdx_903_ecustom--RenegotiatedAmount_iI_pn5n6_c20160731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenDunkleCTWCWellingtonAssetHoldingsMember__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember_zOohj1Gn3vQl" title="Renegotiated amount">1.5</span> million plus 6% interest once there is positive quarterly EBITDA from the first plant of Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 28, 2018, the Company entered into a short-term loan with Steven Sadaka, with a principal balance of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenSadakaMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zu87WEczu3j4" title="Principal balance">100,000</span> due and payable on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20180228__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenSadakaMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zMFBKW06Do0a" title="Maturity date">May 1, 2018</span>. The note does not accrue interest, however the Company provided <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20180228__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenSadakaMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_zxW4nqDAfuBa" title="Shares, conversion of convertible securities">2,000,000</span> inducement shares to secure the note. These inducement shares were valued at $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20180228__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenSadakaMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_z2fp7yk5nas5" title="Conversion of convertible securities, value">84,000</span>. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $<span id="xdx_90E_ecustom--AmountToBePaidOutOfFutureGrossRevenues_c20180228__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StevenSadakaMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zifPCjO9sbk" title="Amount to be paid out of future gross revenues">100,000</span> is to be paid out of future gross revenues to satisfy this note in full.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Christopher Jemapete, with a principal balance of $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_c20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z203glGYplKl" title="Principal balance">50,000</span> due and payable on <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zCoGOwvRQMgg" title="Maturity date">May 16, 2019</span>. The note carried an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_ziwItaMVMKfk" title="Interest rate">5</span>% plus the company issued <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_zQUtWQUkmMDb" title="Shares, conversion of convertible securities">1,250,000</span> inducement shares to secure the note. These inducement shares were valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_zvwWElS3kPp7" title="Conversion of convertible securities, value">36,250</span>. As of June 30, 2018 accrued interest on this note is $<span id="xdx_900_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20180630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zIkXsgb4Cexa" title="Interest payable">315</span>. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $<span id="xdx_903_ecustom--AmountToBePaidOutOfFutureGrossRevenues_pp2d_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ChristopherJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zMWcIrRaR231" title="Amount to be paid out of future gross revenues">50,315.07</span> is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 15, 2018, the Company entered into a short-term loan with Pamela Jemapete, with a principal balance of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zV4BsRtsxfse" title="Principal balance">50,000</span> due and payable on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zneNKybfWo39" title="Maturity date">May 16, 2019</span>. The note carried an interest rate of <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_z5ND7mc5avJk" title="Interest rate">5</span>% plus the company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_zaef5CstWhHj" title="Number of shares issued">1,250,000</span> inducement shares to secure the note. These inducement shares were valued at $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember__us-gaap--StatementEquityComponentsAxis__custom--InducementSharesMember_zLtGm5T9NO25" title="Number of shares issued, value">36,250</span>. As of June 30, 2018 accrued interest on this note is $<span id="xdx_90E_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20180630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zRc6t5bgdbk5" title="Accrued interest, value">315</span>. The note was renegotiated during the Company’s Chapter 11 proceedings, and as per the Plan Confirmation, it is agreed that $<span id="xdx_90B_ecustom--AmountToBePaidOutOfFutureGrossRevenues_pp2d_c20180515__20180515__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--PamelaJemapeteMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--LoansPayableMember_zkyfj3Pq4683" title="Amount to be paid out of future gross revenues">50,315.07</span> is to be paid out of future gross revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes Payable – Other</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining <span id="xdx_907_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zyMljLDlvUB4" title="Business acquisition, percentage">49</span>% of AMG Energy Group. The note had a principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zsH54NJ1Fl1c" title="Debt instrument principal amount">96,570</span> and accrued interest at a rate of six percent (<span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zKGpKSRFDQta" title="Debt interest rate">6</span>%) per annum. As of December 31, 2018, the total interest accrued on the note was $14,382.2. <span id="xdx_90E_ecustom--RenegotiatedNotesDescription_c20160701__20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zPRhtBLj8P0k" title="Renegotiated notes, description">The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $<span id="xdx_900_ecustom--RenegotiatedAmount_iI_c20160731__us-gaap--BusinessAcquisitionAxis__custom--AMGEnergyGroupMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--NotesPayableOtherPayablesMember_zSxa8Y1GglC7" title="Renegotiated amount">96,570</span> is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrta1mcoKQq6" title="Debt instrument principal amount">143,000</span> due and payable on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_c20171101__20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zpcholiNFSs7" title="Debt instrument maturity date">May 30, 2018</span>. The note carried an <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zp8Wi4YEHjF4" title="Debt interest rate">8</span>% one-time interest charge, a $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZt4oVOE0Ne9" title="Original issue discount">43,000</span> original issue discount and a <span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20171101__20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zrWM2BRtNp11" title="Debt instrument conversion discount rate, percentage">35</span>% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20171101__20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zkbK3jMadUJk" title="Shares, conversion of convertible securities">500,000</span> inducement shares to secure the note. These inducement shares were valued at $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20171101__20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyXrXRUmsL2e" title="Conversion of convertible securities, value">39,500</span>. In May 2018, the company made two principal payments totaling $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentPrincipal_c20180501__20180531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zhzfQm88EBAj" title="Debt instrument principal payments">40,000</span>. The note went into default on June 1, 2018, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a subsequent note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZELYneEchXb" title="Renegotiated debt">100,000</span> out of <span id="xdx_90D_ecustom--PercentageOfFutureGrossRevenue_pid_dp_uPure_c20171101__20171130__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3V0rc4e5Hkj" title="Percentage of future gross revenue">5</span>% of the future gross revenue of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2018, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_c20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zoJf51O3Mde3" title="Debt instrument principal amount">165,000</span> due and payable on <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_c20180201__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z3iE1xtLv2C8" title="Debt instrument maturity date">September 21, 2018</span>. The note carries an <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwVvDTCG53S8" title="Debt interest rate">8</span>% one-time interest charge, a $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zONp7le56YO4" title="Original issue discount">15,000</span> original issue discount and a <span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionRatio1_pid_uPure_c20180201__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZnm15d3rhXk" title="Debt instrument conversion discount rate, percentage">40</span>% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20180201__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z5Ux2oOCeAJ9" title="Shares, conversion of convertible securities">500,000</span> inducement shares to secure the note. These inducement shares were valued at $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20180201__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNg07kRS54df" title="Conversion of convertible securities, value">14,500</span>. The Note went into default on June 1, 2018, through a cross default provision with another Note to Hoppel, and incurred a 40% penalty of the outstanding balance immediately prior to the default event. On August 30, 2018, Hoppel sued the Company in Superior Court of the State of California County of San Diego Central District. That case was staid on October 22, 2018, when the Company filed for Chapter 11 protection in the US Bankruptcy Court in the Southern District of Florida. Negotiations took place and a settlement was reached on this note and a prior note, and confirmed as part of the Plan Confirmation Order, that Hoppel would be paid a total of $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcbZ6oowowOa" title="Renegotiated debt">100,000</span> out of <span id="xdx_90D_ecustom--PercentageOfFutureGrossRevenue_pid_dp_uPure_c20180201__20180228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--LucasHoppelMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zKoMvGmJnHO" title="Percentage of future gross revenue">5</span>% of the future gross revenue of the Company to settle both notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 27, 2019, the Company entered into an agreement with another creditor, such that its debt will be reduced from $<span id="xdx_90E_eus-gaap--LongTermNotesPayable_iI_c20190326_zUX7xa7F37ce" title="Notes payable, noncurrent">32,000</span> to $<span id="xdx_909_eus-gaap--LongTermNotesPayable_iI_c20190327_zRq8RWXAEkWc" title="Notes payable, noncurrent">20,000</span> payable out of future gross revenues, upon the bankruptcy court’s acceptance of the Company’s plan of reorganization. The Plan was confirmed by the Court on September 18, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zTn3yE8Gf57d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5GyhuFxDl7k" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zAj9T7ibgA55" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_z0UrhqtVAUF1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_maNPzXA3_zqLQNyAyfZbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short Term Convertible Note – Related Party, including interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">371,908</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzXA3_zgtdB5ssfCr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short Term Chapter 11 Settlement</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongTermNotesPayableAfterCapitalInvestmentReceived_iI_pp0p0_maNPzXA3_zxjaCaTnHFIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long Term Notes Payable after capital investment, incl interest</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">276,944</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzXA3_ziDDWPuTqYid" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzXA3_zUgeqoW7lmOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzXA3_zsI5UBLJ0Fzk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzXA3_zn2nPwj1fJ38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzXA3_zrVX0KhV9if1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,386,984</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AA_z67lbhluwTEc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the $<span id="xdx_906_eus-gaap--NotesPayable_iI_pp0p0_c20230930_zUj8NLGZu8q1" title="TOTAL NOTES">3,386,984</span> payable as of September 30, 2023, $<span id="xdx_902_ecustom--DueOutOfLongTermFutureRevenue_iI_pp0p0_c20230930_zCwzGDbUit7" title="Due out of long term future revenue">2,738,132</span> is due out of future revenue or future profits with no specific due date, and another $<span id="xdx_90F_ecustom--DueRelatedToLongTermNotesPayableCapitalInvestment_iI_pp0p0_c20230930_zxBW3p7mpek" title="Due related to long term notes payable capital investment">275,000</span> is due only after a significant capital investment. $<span id="xdx_909_ecustom--NotesPayableAmountToBeDischarged_iI_pp0p0_c20230930_zelMLun7sndf" title="Notes payable amount to be discharged">2,417,502</span> of the $<span id="xdx_90B_ecustom--DueOutOfLongTermFutureRevenue_iI_pp0p0_c20230930_znzqrBP63UQi" title="Due out of long term future revenue">2,738,132</span> will be discharged if not paid by September 18, 2024, which is 5 years after the Company exited Chapter 11. The remaining debt that would not be discharged is $<span id="xdx_904_eus-gaap--OtherLiabilities_iI_c20230930_zJUs86xlgegh" title="Due to related parties">969,482</span>, consisting of $<span id="xdx_908_eus-gaap--OtherLiabilities_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJTBh8USRI98" title="Due to related parties">849,482</span> due to related parties, and $<span id="xdx_90F_eus-gaap--OtherLiabilities_iI_c20230930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--OtherRelatedPartyMember_zXX3kJC6GRHc" title="Due to related parties">120,000</span> due to others.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 50000 0.10 The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants P5Y 333333 25000 accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 50,000 every 12 months instead of interest, with a minimum of 50,000 warrants 0.13 192308 50000 0.10 The Note is convertible, at the option of the lender, into common shares of the Company at 15 cents per share, plus a warrant with a strike price of 25 cents per share and a 5-year expiration, for a total of 333,333 shares and warrants P5Y 333333 100000 0.13 769231 150000 accrued warrants, with a strike price of 15 cents and an expiration of 5 years, at the rate of 100,000 every 6 months instead of interest. It may convert into common stock at $0.13/share at the option of the holder for a total of 1,153,846 shares P5Y 0.13 1153846 250000 0.13 1923077 0.06 The renegotiated amounts, as per the Plan Confirmation are all to be paid from 50% of the future net profits and discharged to the extent unpaid five years after the Plan effective date of September 18, 2019. 240990 579942 1500000 100000 2018-05-01 2000000 84000 100000 50000 2019-05-16 0.05 1250000 36250 315 50315.07 50000 2019-05-16 0.05 1250000 36250 315 50315.07 0.49 96570 0.06 The Company renegotiated this note during its Chapter 11 proceedings, and as per the Plan Confirmation, now the $96,570 is to be paid with no interest out of the same 50% of the future net profits of the Company as the notes mentioned above, if any, or discharged to the extent unpaid five years after September 18, 2019 96570 143000 2018-05-30 0.08 43000 35 500000 39500 40000 100000 0.05 165000 2018-09-21 0.08 15000 40 500000 14500 100000 0.05 32000 20000 <p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zTn3yE8Gf57d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of all debts indicated in the Notes above is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_z5GyhuFxDl7k" style="display: none">SCHEDULE OF NOTES PAYABLE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Notes Payable</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20230930_zAj9T7ibgA55" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49E_20221231_z0UrhqtVAUF1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--ConvertibleNotesPayableCurrent_iI_pp0p0_maNPzXA3_zqLQNyAyfZbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Short Term Convertible Note – Related Party, including interest</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">371,908</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">0</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--NotesPayableToBankNoncurrent_iI_pp0p0_maNPzXA3_zgtdB5ssfCr5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Short Term Chapter 11 Settlement</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--LongTermNotesPayableAfterCapitalInvestmentReceived_iI_pp0p0_maNPzXA3_zxjaCaTnHFIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long Term Notes Payable after capital investment, incl interest</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">276,944</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotesPayableFromFutureRevenueRelatedParty_iI_pp0p0_maNPzXA3_ziDDWPuTqYid" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long Term Notes Payable from future revenue — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,700,630</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--LongTermNotesPayableFromFutureRevenueOther_iI_pp0p0_maNPzXA3_zUgeqoW7lmOb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Long Term Notes Payable from future revenue — Other</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">120,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--LongTermNotePayableFromFutureProfitsRelatedParty_iI_pp0p0_maNPzXA3_zsI5UBLJ0Fzk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Long Term Note Payable from future profits — Related Party</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">820,932</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--LongTermNotePayableFromFutureProfitsOther_iI_pp0p0_maNPzXA3_zn2nPwj1fJ38" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Long Term Note Payable from future profits — Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">96,570</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--NotesPayable_iTI_pp0p0_mtNPzXA3_zrVX0KhV9if1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">TOTAL NOTES</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,386,984</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,788,132</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 371908 0 0 50000 276944 0 1700630 1700630 120000 120000 820932 820932 96570 96570 3386984 2788132 3386984 2738132 275000 2417502 2738132 969482 849482 120000 <p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z7w0EnZrTnPl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82B_zOBFEzxo8Eb">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total number of shares of capital stock, which the Company has authority to issue, is <span id="xdx_90E_eus-gaap--CapitalUnitsAuthorized_iI_pn6n6_c20230930_zQCVRQwokLY1" title="Capital units, authorized">1,010</span> million, <span id="xdx_900_eus-gaap--CommonStockSharesAuthorized_iI_pn9n9_c20230930_zutLlgtTi7o" title="Common stock, shares authorized">1</span> billion of which are designated as common stock at $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20230930_z2CG7J2go6ni" title="Common stock, par value">0.001</span> par value (the “Common Stock”) and <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_pn6n6_c20230930_zTLXjYTTRqjd" title="Preferred stock, shares authorized">10</span> million of which are designated as preferred stock par value $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20230930_zu2cZiqFjqPb" title="Preferred stock, par value">0.001</span> (the “Preferred Stock”). As of September 30, 2023, the Company had <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20230930_zbGCGjkzSaw9" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20230930_zhtr5Brbq41g" title="Common stock, shares outstanding">302,750,963</span></span> shares of Common Stock issued and outstanding and <span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_do_c20230930_zHPZAGGh27Ca" title="Preferred stock, shares Issued">no</span> shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, the Company issued an aggregate of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230101__20230930_zwJJQOZIpAxb" title="Number of shares issued for services, shares">174,191</span> shares of its common stock for services valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20230101__20230930_zwmlPd14iTrc" title="Number of shares issued for services, value">29,300</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_908_ecustom--WarrantsIssuedForService_c20230101__20230930_z5kWG6iCzDm6" title="Warrants issued for services">364,000</span> warrants were issued for services. Using a Black-Scholes asset pricing model, these had a value of $<span id="xdx_90D_ecustom--WarrantsIssuedDuringPeriodValueIssuedForServices_c20230101__20230930_z8tHyPsizdi7" title="Warrants issued for services, value">48,447</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_908_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares_c20230101__20230930_z3ULBmlKOan1" title="Issuance of common stock and warrants for cash through PPM, shares">6,684,998</span> shares of common stock were issued for cash of $<span id="xdx_90D_ecustom--IssuanceOfCommonStockAndWarrantsForCashThroughPpm_pp0p0_c20230101__20230930_zVk2nIlAyXml" title="Issuance of common stock and warrants for cash through PPM">1,002,772</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_90B_ecustom--WarrantsExercisedShare_c20230101__20230930_zuGNCBhLztWj" title="Warrants exercised share, shares">5,950,148</span> warrants were exercised for proceeds of $<span id="xdx_90E_ecustom--WarrantsExercised_c20230101__20230930_zCM03dPrJxe5" title="Warrants exercised">97,250</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_90C_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_c20230101__20230930_zOhSZASYbSn2" title="Number of warrants expired">2,067,999</span> warrants expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20230101__20230930_zkykAy7dwW3l" title="Unvested options expired">7,050,000</span> unvested options expired and <span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod_c20230101__20230930_zrefySG2hF91" title="Unvested options expired">125,000</span> vested options expired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20230930_zXxiZ8ymzUIf" title="Number of stock options vested, shares">4,385,000</span> stock options vested. Using a Black-Scholes asset pricing model, these had a value of $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20230101__20230930_zIDbq10AuhQh" title="Number of stock options vested, value">637,028</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September 30, 2023, <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20230930_zyyCg9gM8Xq3" title="Number of shares unvested">17,150,000</span> stock options were issued and unvested. Using a Black-Scholes asset pricing model, these have a value of $<span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue_c20230101__20230930_z2ER3Js3ANkh" title="Options issued and unvested value">2,835,613</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1010000000 1000000000 0.001 10000000 0.001 302750963 302750963 0 174191 29300 364000 48447 6684998 1002772 5950148 97250 2067999 7050000 125000 4385000 637028 17150000 2835613 <p id="xdx_80B_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zjteK54K8J7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 - <span><span id="xdx_828_z8RYcfwOn8Ke">COMMITMENTS AND CONTINGENCIES</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Litigation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. The Company is not in any litigation at this time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cybersecurity</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No material cybersecurity breach has occurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently leases office and laboratory space in Palm Beach Gardens, FL, that is classified as operating lease right-of-use (“ROU”) assets and operating lease liabilities in the Company’s consolidated balance sheet. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date for leases exceeding 12 months. The lease period was for twenty-four (24) months from November 1, 2019, to October 31, 2021. <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zNwe469bFwj1" title="Lease extension period">This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024</span>. Annual rent commenced at $<span id="xdx_906_ecustom--AnnualRent_pp0p0_c20230101__20230930_zgcBJhXQD4Nh" title="Annual rent">84,100</span> per annum and increased <span id="xdx_90B_ecustom--PercentageOfIncreaseInRentPerYear_pid_dp_uPure_c20230101__20230930_zKGRDndiLuRb" title="Percentage of increase in rent per year">3</span>% per year. The latest amendment adjusted the lease to $<span id="xdx_907_eus-gaap--OperatingLeaseExpense_pp0p0_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zGyQ7sHR2hz1" title="Lease expense">102,950</span> per annum and increases at <span id="xdx_909_ecustom--PercentageOfIncreaseInRentPerYear_pid_dp_uPure_c20230101__20230930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeAndLaboratorySpaceMember_zmyKDh89Avg" title="Percentage of increase in rent per year">3</span>% per year. Tenant is also required to cover operating costs that are estimated at $<span id="xdx_90E_eus-gaap--OperatingLeaseCost_pp0p0_c20230101__20230930_zMSaNwj5SH1f" title="Operating costs">3,600</span> per month. Operating lease expense is recognized on a straight-line basis over the lease term and is included in General &amp; Administrative expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 842 was effective for us beginning January 1, 2019. The adoption had a material impact on our consolidated balance sheets, but did not have a material impact on our consolidated income statements. The most significant impact was the recognition of ROU assets and lease liabilities for operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company leases land in Arcadia, FL where it grows king grass. The original lease began on September 1, 2020, and was for <span id="xdx_905_eus-gaap--AreaOfLand_iI_uAcres_c20200901_zbe0yFep1IQh" title="Acres">18.2</span> acres at an annual cost of $<span id="xdx_906_eus-gaap--LeaseCost_c20200901__20200901_z20yidx0Afo7" title="Lease cost">6,370</span> that the Company has the right to renew for a total of <span id="xdx_902_ecustom--LeaseRenewalTerm_dtY_c20200901__20200901_zMQX9DE68tU8" title="Lease renewal term">5</span> years. A second lease began on March 31, 2023, for an additional <span id="xdx_908_eus-gaap--AreaOfLand_iI_uAcres_c20230930_zO0CrBcvVcNf" title="Acres">167.6</span> acres at a cost of $<span id="xdx_901_eus-gaap--LeaseCost_c20230101__20230930_z2gWb1ityQg2" title="Lease cost">24,721</span> every 6 months that the Company also can continue for up to <span id="xdx_90C_ecustom--LeaseRenewalTerm_dtY_c20230101__20230930_zo89EA9Wydy4" title="Lease renewal term">5</span> years. Since those leases can be terminated at will, they are not included in the ROU or lease liability on the Company’s balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent expense for the nine months ending September 30, 2023, and 2022, were $<span id="xdx_908_eus-gaap--PaymentsForRent_c20230101__20230930_zni7m2k7ndsb" title="Rent expense">183,537</span> and $<span id="xdx_90A_eus-gaap--PaymentsForRent_c20220101__20220930_zg8pWjsAh0la" title="Rent expense">106,631</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zQZV01gmhIV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B0_zBOP0bama7O" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930_zthN5V8jIN37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zmo4R7VIAgWh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzR4B_zEszSS10J5id" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">101,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">95,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzR4B_z5jeNH3WJRck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,793</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzR4B_zu5vhLHmESDg" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">110,698</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,155</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_z5wgnkDCAE6g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zuTnhj6oJCa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8BC_zEVw1gS50w4d" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930_zlEP0246aRf6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zaR4kALTDrI9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: right">2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">24,715</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zjyIp4HyOzqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z4XEhZ5wvo86" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zqBCF9avdQJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">110,698</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zIMGQXP4tvQg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> This had been extended for one year until October 31, 2022, and was further extended for two more years until October 31, 2024 84100 0.03 102950 0.03 3600 18.2 6370 P5Y 167.6 24721 P5Y 183537 106631 <p id="xdx_895_esrt--ScheduleOfCondensedBalanceSheetTableTextBlock_zQZV01gmhIV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized the following related to leases in its Consolidated Balance Sheet:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8B0_zBOP0bama7O" style="display: none">SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">PERIOD ENDED</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930_zthN5V8jIN37" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20221231_zmo4R7VIAgWh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Right of Use Lease Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzR4B_zEszSS10J5id" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-left: 10pt">Current portion</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">101,905</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">95,172</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzR4B_z5jeNH3WJRck" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Long-term portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,793</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,983</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzR4B_zu5vhLHmESDg" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">110,698</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,155</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 101905 95172 8793 85983 110698 181155 <p id="xdx_893_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zuTnhj6oJCa2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2023, the total future minimum lease payments in respect of leased premises are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"> <span id="xdx_8BC_zEVw1gS50w4d" style="display: none">SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS</span></span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">YEAR ENDED</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20230930_zlEP0246aRf6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MINIMUM</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DUE</b></span></p></td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_zaR4kALTDrI9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: right">2023</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">24,715</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_zjyIp4HyOzqk" style="vertical-align: bottom; background-color: White"> <td style="text-align: right">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,983</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_z4XEhZ5wvo86" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: right; padding-bottom: 1.5pt">2025</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_zqBCF9avdQJi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 1.5pt">TOTAL</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">110,698</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> </table> 24715 85983 0 110698 <p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zNnjsT0Pgc66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82C_zshSI58TDonk">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related Party Transactions</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows FASB ASC subtopic 850-10, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term notes payable, convertible notes, and contingent liabilities issued to related parties are described in NOTE 6.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A board resolution was passed on February 13, 2020, that pledged the patents and pending patents to secure the back pay claims of Ben Slager, CEO, Anthony Santelli, CFO, and Charles Sills, Director. This was done to ensure the continued involvement of management to build the Company while they receive less than full salaries.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_z56AimnJe4tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_820_z9kCLCmYkJKf">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date the financial statements were issued. Based on this evaluation, the Company has identified the following subsequent events:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From October 1, 2023, to the date of this filing, the Company issued <span id="xdx_900_ecustom--WarrantsIssuedForService_c20231001__20231107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZhuANGYegL4" title="Warrants issued for services, shares">350,000</span> warrants for services. Using the Black-Scholes pricing model, these were valued at $<span id="xdx_90B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20231001__20231107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zlLuKQW7f8Ta" title="Warrants issued for services">29,991</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From October 1, 2023, to the date of this filing, the Company issued convertible notes to related parties for $<span id="xdx_908_eus-gaap--ConvertibleDebt_iI_c20231107__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zOvxCWSeOW8i" title="Convertible note">15,000</span>.</span></p> 350000 29991 15000 EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 49 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 168 220 1 false 50 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://bluebiofuels.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://bluebiofuels.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statement of Operations (Unaudited) Sheet http://bluebiofuels.com/role/StatementOfOperations Consolidated Statement of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Sheet http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://bluebiofuels.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION Sheet http://bluebiofuels.com/role/Organization ORGANIZATION Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://bluebiofuels.com/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://bluebiofuels.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 00000012 - Disclosure - PATENTS Sheet http://bluebiofuels.com/role/Patents PATENTS Notes 12 false false R13.htm 00000013 - Disclosure - DEBT Sheet http://bluebiofuels.com/role/Debt DEBT Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://bluebiofuels.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 14 false false R15.htm 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://bluebiofuels.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://bluebiofuels.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 16 false false R17.htm 00000017 - Disclosure - SUBSEQUENT EVENTS Sheet http://bluebiofuels.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 17 false false R18.htm 00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://bluebiofuels.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://bluebiofuels.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - DEBT (Tables) Sheet http://bluebiofuels.com/role/DebtTables DEBT (Tables) Tables http://bluebiofuels.com/role/Debt 21 false false R22.htm 00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://bluebiofuels.com/role/CommitmentsAndContingencies 22 false false R23.htm 00000023 - Disclosure - ORGANIZATION (Details Narrative) Sheet http://bluebiofuels.com/role/OrganizationDetailsNarrative ORGANIZATION (Details Narrative) Details http://bluebiofuels.com/role/Organization 23 false false R24.htm 00000024 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://bluebiofuels.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://bluebiofuels.com/role/GoingConcern 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Sheet http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details) Details 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 27 false false R28.htm 00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://bluebiofuels.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - PATENTS (Details Narrative) Sheet http://bluebiofuels.com/role/PatentsDetailsNarrative PATENTS (Details Narrative) Details http://bluebiofuels.com/role/Patents 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details) Notes http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails SCHEDULE OF NOTES PAYABLE (Details) Details 30 false false R31.htm 00000031 - Disclosure - DEBT (Details Narrative) Sheet http://bluebiofuels.com/role/DebtDetailsNarrative DEBT (Details Narrative) Details http://bluebiofuels.com/role/DebtTables 31 false false R32.htm 00000032 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://bluebiofuels.com/role/StockholdersEquity 32 false false R33.htm 00000033 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) Sheet http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details) Details 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details) Details 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://bluebiofuels.com/role/CommitmentsAndContingenciesTables 35 false false R36.htm 00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://bluebiofuels.com/role/SubsequentEvents 36 false false All Reports Book All Reports biof-20230930.xsd biof-20230930_cal.xml biof-20230930_def.xml biof-20230930_lab.xml biof-20230930_pre.xml form10-q.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 54 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "BIOF", "nsuri": "http://bluebiofuels.com/20230930", "dts": { "schema": { "local": [ "biof-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "biof-20230930_cal.xml" ] }, "definitionLink": { "local": [ "biof-20230930_def.xml" ] }, "labelLink": { "local": [ "biof-20230930_lab.xml" ] }, "presentationLink": { "local": [ "biof-20230930_pre.xml" ] }, "inline": { "local": [ "form10-q.htm" ] } }, "keyStandard": 183, "keyCustom": 37, "axisStandard": 13, "axisCustom": 0, "memberStandard": 19, "memberCustom": 28, "hidden": { "total": 84, "http://bluebiofuels.com/20230930": 22, "http://fasb.org/us-gaap/2023": 57, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 168, "entityCount": 1, "segmentCount": 50, "elementCount": 367, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 548, "http://xbrl.sec.gov/dei/2023": 29, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://bluebiofuels.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://bluebiofuels.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockSharesIssued", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role": "http://bluebiofuels.com/role/StatementOfOperations", "longName": "00000004 - Statement - Consolidated Statement of Operations (Unaudited)", "shortName": "Consolidated Statement of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-03-31_us-gaap_CommonStockMember", "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "longName": "00000006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-04-012023-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R7": { "role": "http://bluebiofuels.com/role/StatementsOfCashFlows", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R8": { "role": "http://bluebiofuels.com/role/Organization", "longName": "00000008 - Disclosure - ORGANIZATION", "shortName": "ORGANIZATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://bluebiofuels.com/role/GoingConcern", "longName": "00000009 - Disclosure - GOING CONCERN", "shortName": "GOING CONCERN", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://bluebiofuels.com/role/PropertyAndEquipment", "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://bluebiofuels.com/role/Patents", "longName": "00000012 - Disclosure - PATENTS", "shortName": "PATENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://bluebiofuels.com/role/Debt", "longName": "00000013 - Disclosure - DEBT", "shortName": "DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://bluebiofuels.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "shortName": "STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://bluebiofuels.com/role/CommitmentsAndContingencies", "longName": "00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://bluebiofuels.com/role/RelatedPartyTransactions", "longName": "00000016 - Disclosure - RELATED PARTY TRANSACTIONS", "shortName": "RELATED PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://bluebiofuels.com/role/SubsequentEvents", "longName": "00000017 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000018 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://bluebiofuels.com/role/PropertyAndEquipmentTables", "longName": "00000020 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://bluebiofuels.com/role/DebtTables", "longName": "00000021 - Disclosure - DEBT (Tables)", "shortName": "DEBT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables", "longName": "00000022 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://bluebiofuels.com/role/OrganizationDetailsNarrative", "longName": "00000023 - Disclosure - ORGANIZATION (Details Narrative)", "shortName": "ORGANIZATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BIOF:RenewableFuelDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BIOF:RenewableFuelDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R24": { "role": "http://bluebiofuels.com/role/GoingConcernDetailsNarrative", "longName": "00000024 - Disclosure - GOING CONCERN (Details Narrative)", "shortName": "GOING CONCERN (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R25": { "role": "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "longName": "00000025 - Disclosure - SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "shortName": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2023-01-012023-09-30_custom_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-09-30_custom_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember_us-gaap_WarrantMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "BIOF:StockbasedCompensationValuationMethodologyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R26": { "role": "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "longName": "00000027 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30_us-gaap_BuildingImprovementsMember", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R28": { "role": "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000028 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R29": { "role": "http://bluebiofuels.com/role/PatentsDetailsNarrative", "longName": "00000029 - Disclosure - PATENTS (Details Narrative)", "shortName": "PATENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:FiniteLivedPatentsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails", "longName": "00000030 - Disclosure - SCHEDULE OF NOTES PAYABLE (Details)", "shortName": "SCHEDULE OF NOTES PAYABLE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://bluebiofuels.com/role/DebtDetailsNarrative", "longName": "00000031 - Disclosure - DEBT (Details Narrative)", "shortName": "DEBT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:NotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2019-03-27", "name": "us-gaap:LongTermNotesPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R32": { "role": "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "longName": "00000032 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CapitalUnitsAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BIOF:WarrantsIssuedDuringPeriodValueIssuedForServices", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R33": { "role": "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails", "longName": "00000033 - Disclosure - SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details)", "shortName": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:OperatingLeaseLiability", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "srt:ScheduleOfCondensedBalanceSheetTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R34": { "role": "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails", "longName": "00000034 - Disclosure - SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "shortName": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R35": { "role": "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BIOF:AnnualRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "BIOF:AnnualRent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R36": { "role": "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative", "longName": "00000036 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "BIOF:WarrantsIssuedForService", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-10-012023-11-07_us-gaap_SubsequentEventMember", "name": "BIOF:WarrantsIssuedForService", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } } }, "tag": { "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net of accumulated depreciation and amortization of $214,125 and $127,178 at September 30, 2023 and December 31,2022, respectively", "totalLabel": "Property and Equipment", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r376", "r385", "r495" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Income (Loss) before provisions for income taxes", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r101", "r143", "r150", "r169", "r174", "r178", "r180", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r328", "r329", "r386", "r483", "r546" ] }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF BLACK-SCHOLES OPTION PRICING MODELS FOR WARRANT-BASED STOCK COMPENSATION", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": [ "r8", "r9", "r43" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r341", "r494" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r81" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r342", "r494" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and Equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r110", "r113", "r383" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r515" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT ASSETS", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r120", "r127", "r143", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r315", "r317", "r329", "r495", "r546", "r547", "r582" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Security deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r530" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r258", "r348", "r349", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r410", "r411", "r412", "r413", "r414", "r433", "r435", "r465", "r581" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r507" ] }, "BIOF_MarkKochMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "MarkKochMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mark Koch [Member]", "documentation": "Mark Koch [Member]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r136" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r520" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Earnings per share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r134", "r152", "r153", "r154", "r155", "r156", "r162", "r164", "r165", "r166", "r167", "r327", "r328", "r375", "r388", "r481" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash from (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r136" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r523" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r82", "r83", "r84" ] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayableMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_AreaOfLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfLand", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Acres", "documentation": "Area of land held." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation and amortization on property and equipment", "negatedLabel": "Less Accumulated Depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r38", "r124", "r384" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations:", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r169", "r174", "r178", "r180", "r483" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred wages and director\u2019s fees - Related party", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r16", "r495" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r70" ] }, "us-gaap_NotesPayableToBankCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableToBankCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Chapter 11 Settlement", "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r497", "r498", "r501", "r502", "r503", "r504", "r593", "r596" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r33", "r34", "r35", "r108", "r109", "r111", "r112" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment of Debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r533" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument conversion discount rate, percentage", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r19", "r41", "r97", "r98", "r208" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "BIOF_StevenSadakaMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StevenSadakaMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Steven Sadaka [Member]", "documentation": "Steven Sadaka [Member]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of stock options vested, value", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r283" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r513" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r37" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 3.0 }, "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of assets", "negatedTerseLabel": "Loss on Disposal of assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r534" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible, conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r94", "r208" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "BIOF_PamelaJemapeteMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "PamelaJemapeteMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pamela Jemapete [Member]", "documentation": "Pamela Jemapete [Member]" } } }, "auth_ref": [] }, "BIOF_LucasHoppelMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LucasHoppelMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lucas Hoppel [Member]", "documentation": "Lucas Hoppel [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r336", "r354" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r135", "r137", "r138" ] }, "BIOF_OtherRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "OtherRelatedPartyMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other Related Party [Member]", "documentation": "Other Related Party [Member]" } } }, "auth_ref": [] }, "BIOF_GrantsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "GrantsReceived", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Grants received", "documentation": "Grants received.", "label": "GrantsReceived" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "BIOF_OfficeAndLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "OfficeAndLaboratorySpaceMember", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Office and Laboratory Space [Member]", "documentation": "Office and Laboratory Space [Member]" } } }, "auth_ref": [] }, "BIOF_StockholdersEquityDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StockholdersEquityDeficit", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL EQUITY (DEFICIT)", "documentation": "Stockholders Equity Deficit.", "label": "Stockholders Equity Deficit" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument principal payments", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r20" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r53", "r54", "r206", "r337", "r486", "r487" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r258", "r348", "r349", "r410", "r411", "r412", "r413", "r414", "r433", "r435", "r465" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r118", "r131", "r132", "r133", "r147", "r148", "r149", "r151", "r157", "r159", "r168", "r185", "r186", "r246", "r294", "r295", "r296", "r311", "r312", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r330", "r331", "r332", "r333", "r334", "r335", "r344", "r391", "r392", "r393", "r405", "r458" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "BIOF_ConvertibleDebtOneMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ConvertibleDebtOneMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt One [Member]", "documentation": "Convertible Debt One [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OtherLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLongTermNotesPayable", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Notes Payable \u2014 Other", "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r20" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reconciliation of net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original issue discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r52", "r54", "r549" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Provisions for income taxes", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r107", "r115", "r158", "r159", "r172", "r306", "r313", "r389" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total other (income) expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r78" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r37" ] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LONG-TERM ASSETS", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r143", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r315", "r317", "r329", "r546", "r547", "r582" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r509" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r146", "r206", "r207", "r208", "r209", "r210", "r212", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r337", "r485", "r486", "r487", "r488", "r489", "r535" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r339" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r41", "r42", "r52", "r53", "r54", "r59", "r96", "r98", "r146", "r206", "r207", "r208", "r209", "r210", "r212", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r337", "r485", "r486", "r487", "r488", "r489", "r535" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL CURRENT LIABILITIES", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r17", "r121", "r143", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r316", "r317", "r318", "r329", "r495", "r546", "r582", "r583" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Lease Liability - Current", "verboseLabel": "Current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r339" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long term liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease extension period", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r340" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r509" ] }, "BIOF_ConvertibleDebtTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ConvertibleDebtTwoMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Two [Member]", "documentation": "Convertible Debt Two [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r55", "r56", "r439", "r440", "r443" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r18", "r207" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r345", "r346", "r347", "r349", "r352", "r402", "r403", "r404", "r441", "r442", "r443", "r462", "r464" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term assets" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Issuance of options and warrants for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r15", "r143", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r316", "r317", "r318", "r329", "r415", "r482", "r506", "r546", "r582", "r583" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r116", "r485", "r577" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/ScheduleOfLeaseConsolidatedBalanceSheetDetails" ], "lang": { "en-us": { "role": { "label": "Right of Use Lease Liability, net of current portion", "verboseLabel": "Long-term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r339" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r439", "r440", "r443" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r521" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LONG TERM LIABILITIES", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r64", "r65", "r66", "r68", "r143", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r316", "r317", "r318", "r329", "r546", "r582", "r583" ] }, "BIOF_AnimatedFamilyFilmsMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "AnimatedFamilyFilmsMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Animated Family Films [Member]", "documentation": "Animated Family Films [Member]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r509" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest - related party", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r4" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r75", "r105", "r382", "r495", "r536", "r543", "r578" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due to related parties", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r58", "r377", "r411", "r412", "r506", "r594" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Right of Use Assets, net of accumulated amortization", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r338" ] }, "BIOF_IssuanceDateAprilElevenTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateAprilElevenTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 4/11/23 [Member]", "documentation": "Issuance Date April Eleven Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r30", "r32", "r50", "r51", "r183", "r472" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r69", "r234" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest, value", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r57", "r591" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r30", "r32", "r50", "r51", "r183", "r396", "r472" ] }, "BIOF_IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateMarchThirtyFirstTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 3/31/2023 [Member]", "documentation": "Issuance Date March Thirty First Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for services", "verboseLabel": "Warrants issued for services", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r7", "r40", "r99" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r88", "r110", "r113", "r114" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r525" ] }, "BIOF_IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateAprilTwentySixTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 4/26/23 [Member]", "documentation": "Issuance Date April Twenty Six Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Proceeds from the issuance of Convertible Notes", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r23" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - Fully Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r161", "r166" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Interest Payable - Related Party", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r16" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r170", "r171", "r173", "r176", "r177", "r181", "r182", "r183", "r255", "r256", "r361" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding - Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r160", "r166" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r12", "r495" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "BIOF_IssuanceDateJulyThirteenTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateJulyThirteenTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 7/13/23 [Member]", "documentation": "Issuance Date July Thirteen Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense - other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r497", "r498", "r501", "r502", "r503", "r504" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedPatentsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedPatentsGross", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/PatentsDetailsNarrative", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Patents", "verboseLabel": "Finite-Lived Patents, Gross", "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights." } } }, "auth_ref": [ "r87" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r89" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r510" ] }, "BIOF_PilotPlantMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "PilotPlantMember", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pilot Plant [Member]", "documentation": "Pilot Plant [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "BIOF_IssuanceDateJuneFiveTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateJuneFiveTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 6/5/23 [Member]", "documentation": "Issuance Date June Five Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock based compensation for services", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r293", "r301" ] }, "BIOF_IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateJulyTwentySixTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 7/26/23 [Member]", "documentation": "Issuance Date 7/26/23 [Member]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r130", "r304", "r305", "r307", "r308", "r309", "r310", "r400" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research & Development", "verboseLabel": "Research and development expenses", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r61", "r303", "r590" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r348", "r349", "r581" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental schedule of non-cash activities" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "BIOF_StockholdersEquityDeficit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity (deficit)", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r70", "r73", "r74", "r86", "r418", "r434", "r459", "r460", "r495", "r506", "r536", "r543", "r578", "r596" ] }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant, reason for issuance, description", "documentation": "Description of reason for issuing warrant or right." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r336", "r354" ] }, "us-gaap_CapitalUnitsAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsAuthorized", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital units, authorized", "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r126", "r187", "r188", "r478" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r49", "r479" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "DEBT", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r92", "r141", "r205", "r211", "r212", "r213", "r214", "r215", "r216", "r221", "r228", "r229", "r231" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants and options", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r532" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Grants receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r531" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRent", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Rent expense", "documentation": "Cash payments to lessor's for use of assets under operating leases." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r260", "r267", "r286", "r287", "r288", "r289", "r292", "r297", "r298", "r299", "r300" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense - related party", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r79", "r225", "r232", "r488", "r489" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/Organization" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r62", "r100", "r397", "r398" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/GoingConcernDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated losses", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r72", "r99", "r381", "r394", "r395", "r401", "r417", "r495" ] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingImprovementsMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Building Improvements [Member]", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r89" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r82" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unvested options expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r275" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r343" ] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss on disposal of assets", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r5" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Net income (loss) per share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r134", "r152", "r153", "r154", "r155", "r156", "r160", "r162", "r164", "r165", "r166", "r167", "r327", "r328", "r375", "r388", "r481" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalent at beginning of the period", "periodEndLabel": "Cash and cash equivalent at end of the period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r82", "r139" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r144", "r145", "r348", "r349", "r350", "r351", "r410", "r411", "r412", "r413", "r414", "r433", "r435", "r465" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r343" ] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF LEASE CONSOLIDATED BALANCE SHEET", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r529", "r539" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r537", "r538" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations", "http://bluebiofuels.com/role/StatementsOfCashFlows", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income / (Loss):", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r76", "r84", "r106", "r119", "r128", "r129", "r133", "r143", "r150", "r152", "r153", "r154", "r155", "r158", "r159", "r163", "r169", "r174", "r178", "r180", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r328", "r329", "r387", "r436", "r456", "r457", "r483", "r505", "r546" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r343" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expected dividends", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r290" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "2023", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r580" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r580" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r289" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r579" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r90" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r77", "r438" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r291" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r147", "r148", "r149", "r168", "r361", "r399", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r435", "r437", "r438", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r458", "r500" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r302" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 EQUITY", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r142", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r325", "r461", "r463", "r471" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r289", "r290", "r291", "r292" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r261", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r288", "r289", "r290", "r291", "r292" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business acquisition, percentage", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r47" ] }, "us-gaap_DebtInstrumentDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentDescription", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument, description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } } }, "auth_ref": [ "r10", "r41", "r60", "r67", "r103", "r104" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r46", "r48", "r314", "r491", "r492" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vesting of options under the employee, director plan", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r44", "r45", "r262" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid during the period for" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r314", "r491", "r492" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r31" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants expired", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r7", "r69", "r70", "r99" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r294", "r295", "r296", "r405", "r540", "r541", "r542", "r576", "r596" ] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/Patents" ], "lang": { "en-us": { "role": { "label": "PATENTS", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r189" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal of machinery", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r80" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r508" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://bluebiofuels.com/role/DebtTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF NOTES PAYABLE", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expense:" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMachineryAndEquipment", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase of machinery", "documentation": "The cash outflow for acquisition of machinery and equipment." } } }, "auth_ref": [ "r81" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and Equipment, gross", "verboseLabel": "Purchase value", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r89", "r123", "r385" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible note", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r10", "r104", "r592" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r511" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r512" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r102", "r125", "r143", "r169", "r175", "r179", "r184", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r315", "r317", "r329", "r378", "r428", "r495", "r506", "r546", "r547", "r582" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r336", "r354" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r22", "r118", "r131", "r132", "r133", "r147", "r148", "r149", "r151", "r157", "r159", "r168", "r185", "r186", "r246", "r294", "r295", "r296", "r311", "r312", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r330", "r331", "r332", "r333", "r334", "r335", "r344", "r391", "r392", "r393", "r405", "r458" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r516" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r118", "r147", "r148", "r149", "r151", "r157", "r159", "r185", "r186", "r294", "r295", "r296", "r311", "r312", "r319", "r321", "r322", "r324", "r326", "r391", "r393", "r405", "r596" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r497", "r498", "r499", "r501", "r502", "r503", "r504", "r540", "r541", "r576", "r593", "r596" ] }, "BIOF_IssuanceDateAprilFiveTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateAprilFiveTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 4/5/23 [Member]", "documentation": "Issuance Date April Five Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r336", "r354" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r336", "r354" ] }, "BIOF_PercentageOfFutureGrossRevenue": { "xbrltype": "percentItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "PercentageOfFutureGrossRevenue", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of future gross revenue", "documentation": "Percentage of future gross revenue." } } }, "auth_ref": [] }, "BIOF_AmountToBePaidOutOfFutureGrossRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "AmountToBePaidOutOfFutureGrossRevenues", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amount to be paid out of future gross revenues", "documentation": "Amount to be paid out of future gross revenues." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r91", "r190", "r191", "r473", "r545" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r30", "r32", "r50", "r51", "r183", "r472", "r528" ] }, "us-gaap_NotesPayableToBankNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableToBankNoncurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Short Term Chapter 11 Settlement", "documentation": "The total amount due within more than 12 month, or the operating cycle if longer, on all notes payable to banks paid on an installment. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances." } } }, "auth_ref": [ "r10", "r104" ] }, "us-gaap_CostOfGoodsProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsProductLineMember", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r527" ] }, "BIOF_MachineryMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "MachineryMember", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Machinery [Member]", "documentation": "Machinery [Member]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r117", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r476" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable \u2014 Related Party", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r14" ] }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpm": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpm", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash through PPM", "documentation": "Issuance of common stock and warrants for cash through ppm." } } }, "auth_ref": [] }, "us-gaap_NotesPayableOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableOtherPayablesMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes Payable, Other Payables [Member]", "documentation": "A written promise to pay a note to a third party." } } }, "auth_ref": [] }, "BIOF_IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares": { "xbrltype": "sharesItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceOfCommonStockAndWarrantsForCashThroughPpmShares", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock and warrants for cash through PPM, shares", "documentation": "Issuance of common stock and warrants for cash through Ppm shares." } } }, "auth_ref": [] }, "BIOF_DueOutOfLongTermFutureRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "DueOutOfLongTermFutureRevenue", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due out of long term future revenue", "documentation": "Due out of long term future revenue." } } }, "auth_ref": [] }, "BIOF_WarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "WarrantsExercised", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercised", "documentation": "Warrants exercised." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r257", "r259", "r289", "r290", "r291", "r356", "r357", "r390", "r407", "r408", "r466", "r467", "r468", "r469", "r470", "r474", "r475", "r484", "r490", "r493", "r496", "r499", "r544", "r548", "r585", "r586", "r587", "r588", "r589" ] }, "BIOF_NotesPayableAmountToBeDischarged": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "NotesPayableAmountToBeDischarged", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes payable amount to be discharged", "documentation": "Notes payable amount to be discharged." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets", "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes Payable \u2014 Related Party", "verboseLabel": "Notes payable, noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r20" ] }, "BIOF_DueRelatedToLongTermNotesPayableCapitalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "DueRelatedToLongTermNotesPayableCapitalInvestment", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Due related to long term notes payable capital investment", "documentation": "Due related to long term notes payable capital investment." } } }, "auth_ref": [] }, "BIOF_WarrantsExercisedShare": { "xbrltype": "sharesItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "WarrantsExercisedShare", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercised, shares", "verboseLabel": "Warrants exercised share, shares", "documentation": "Warrants exercised share." } } }, "auth_ref": [] }, "BIOF_EdmundBurkeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "EdmundBurkeMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Edmund Burke [Member]", "documentation": "Edmund Burke [Member]" } } }, "auth_ref": [] }, "BIOF_WarrantsIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "WarrantsIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued for services, value", "documentation": "Warrants issued during period value issued for services." } } }, "auth_ref": [] }, "BIOF_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Unvested options expired", "documentation": "Share based compensation arrangement by share based payment award vested options expirations in period.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r259", "r357", "r390", "r407", "r408", "r466", "r467", "r468", "r469", "r470", "r474", "r475", "r484", "r490", "r493", "r496", "r548", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "BIOF_StockIssuedDuringPeriodSharesStockOptionsExercised1": { "xbrltype": "sharesItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Employee stock options exercised, shares", "documentation": "Stock issued during period shares stock options exercised." } } }, "auth_ref": [] }, "BIOF_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedAndUnvestedInPeriodFairValue", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options issued and unvested value", "documentation": "Sharebased compensation arrangement by sharebased payment award options issued and unvested in period fair value." } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r257", "r259", "r289", "r290", "r291", "r356", "r357", "r390", "r407", "r408", "r466", "r467", "r468", "r469", "r470", "r474", "r475", "r484", "r490", "r493", "r496", "r499", "r544", "r548", "r585", "r586", "r587", "r588", "r589" ] }, "BIOF_AnnualRent": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "AnnualRent", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual rent", "documentation": "Annual rent." } } }, "auth_ref": [] }, "BIOF_StockIssuedDuringPeriodValueStockOptionsExercised1": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised1", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Employee stock options exercised", "documentation": "Stock issued during period value stock options exercised1." } } }, "auth_ref": [] }, "BIOF_PercentageOfIncreaseInRentPerYear": { "xbrltype": "percentItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "PercentageOfIncreaseInRentPerYear", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of increase in rent per year", "documentation": "Percentage of increase in rent per year." } } }, "auth_ref": [] }, "BIOF_LeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LeaseRenewalTerm", "presentation": [ "http://bluebiofuels.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lease renewal term", "documentation": "Lease renewal term." } } }, "auth_ref": [] }, "BIOF_WarrantsIssuedForService": { "xbrltype": "sharesItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "WarrantsIssuedForService", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative", "http://bluebiofuels.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants issued for services", "verboseLabel": "Warrants issued for services, shares", "documentation": "Warrants issued for service." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r259", "r357", "r390", "r407", "r408", "r466", "r467", "r468", "r469", "r470", "r474", "r475", "r484", "r490", "r493", "r496", "r548", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "BIOF_IncreaseDecreaseInRightOfUseLease": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IncreaseDecreaseInRightOfUseLease", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right of use lease", "documentation": "Increase decrease in right of use lease." } } }, "auth_ref": [] }, "BIOF_IncreaseDecreaseInGrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IncreaseDecreaseInGrantsReceivable", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Grants receivable", "documentation": "Increase decrease in grants receivable.", "label": "IncreaseDecreaseInGrantsReceivable" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible securities, value", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r22", "r99" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r147", "r148", "r149", "r168", "r361", "r399", "r406", "r409", "r410", "r411", "r412", "r413", "r414", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r429", "r430", "r431", "r432", "r433", "r435", "r437", "r438", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r458", "r500" ] }, "BIOF_PaymentsForPatentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "PaymentsForPatentCosts", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Patent Costs", "documentation": "Payments for patent costs.", "label": "PaymentsForPatentCosts" } } }, "auth_ref": [] }, "BIOF_ChrisKneppersMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ChrisKneppersMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chris Kneppers [Member]", "documentation": "Chris Kneppers [Member]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r520" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r70" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r518", "r520", "r521" ] }, "BIOF_StevenDunkleCTWCWellingtonAssetHoldingsMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StevenDunkleCTWCWellingtonAssetHoldingsMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Steven Dunkle CTWC Wellington Asset Holdings [Member]", "documentation": "Steven Dunkle CTWC Wellington Asset Holdings [Member]" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r519" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services", "verboseLabel": "Number of shares issued for services, value", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "BIOF_IssuanceOfWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceOfWarrantsForServices", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants for services", "documentation": "Issuance of warrants for services.", "label": "IssuanceOfWarrantsForServices" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r520" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficit", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares", "verboseLabel": "Number of shares issued for services, shares", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative", "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL NOTES", "label": "TOTAL NOTES", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r104", "r592" ] }, "BIOF_CashlessConversionOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "CashlessConversionOfWarrants", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cashless conversion of warrants/options", "documentation": "Cashless conversion of warrants." } } }, "auth_ref": [] }, "BIOF_IssuanceOfCommonStockForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceOfCommonStockForServices", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock for services", "documentation": "Issuance of common stock for services.", "label": "IssuanceOfCommonStockForServices" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock; $0.001 par value; 1,000,000,000 shares authorized; 302,750,963 issued and outstanding at September 30, 2023, and 289,941,623 shares issued and outstanding at December 31, 2022.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r380", "r495" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://bluebiofuels.com/role/GoingConcern" ], "lang": { "en-us": { "role": { "label": "GOING CONCERN", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r63" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r522" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r416" ] }, "BIOF_StockbasedCompensationValuationMethodologyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "StockbasedCompensationValuationMethodologyPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based Compensation Valuation Methodology", "documentation": "Stock based Compensation Valuation Methodology [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r69", "r379", "r495" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r70", "r416", "r434", "r596", "r597" ] }, "BIOF_ConversionOfConvertibleDebentureToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ConversionOfConvertibleDebentureToCommonStock", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of convertible debenture to common stock", "documentation": "Conversion of convertible debenture to common stock." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r521" ] }, "BIOF_CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "CommonStockPurchaseWarrantsAndOtherDerivativeFinancialInstrumentsPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants and Other Derivative Financial Instruments", "documentation": "Common Stock Purchase Warrants And Other Derivative Financial Instruments [Policy Text Block]" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "BIOF_RenewableFuelDescription": { "xbrltype": "stringItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "RenewableFuelDescription", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Renewable fuel description", "documentation": "Renewable Fuel Description." } } }, "auth_ref": [] }, "BIOF_RenegotiatedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "RenegotiatedAmount", "crdr": "debit", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Renegotiated amount", "documentation": "Renegotiated amount." } } }, "auth_ref": [] }, "BIOF_LongTermNotesPayableFromFutureRevenueRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LongTermNotesPayableFromFutureRevenueRelatedParty", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Notes Payable from future revenue \u2014 Related Party", "documentation": "Long term notes payable from future revenue related party." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r520" ] }, "BIOF_LongTermNotesPayableAfterCapitalInvestmentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LongTermNotesPayableAfterCapitalInvestmentReceived", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Notes Payable after capital investment, incl interest", "documentation": "Long term notes payable after capital investment received." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskProduct": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskProduct", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dscription of Production", "documentation": "Description of risks that arise due to the volume of revenue generated by a particular product or other reliance placed on the success of that product, and the characteristics of that product that may give rise to the risk (for example, a patent or trademark expiration date). At a minimum, the description informs financial statement users of the general nature of the risk." } } }, "auth_ref": [ "r29", "r31", "r32" ] }, "BIOF_LongTermNotesPayableFromFutureRevenueOther": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LongTermNotesPayableFromFutureRevenueOther", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Notes Payable from future revenue \u2014 Other", "documentation": "Long Term Notes Payable From Future Revenue Other." } } }, "auth_ref": [] }, "BIOF_LongTermNotePayableFromFutureProfitsRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LongTermNotePayableFromFutureProfitsRelatedParty", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Note Payable from future profits \u2014 Related Party", "documentation": "Long term note payable from future profits related party." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r39" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property and equipment, estimated useful life", "verboseLabel": "Estimated Useful Lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "BIOF_LongTermNotePayableFromFutureProfitsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "LongTermNotePayableFromFutureProfitsOther", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Note Payable from future profits \u2014 Other", "documentation": "Long term note payable from future profits other." } } }, "auth_ref": [] }, "BIOF_RenegotiatedNotesDescription": { "xbrltype": "stringItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "RenegotiatedNotesDescription", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Renegotiated notes, description", "documentation": "Renegotiated notes description." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares, conversion of convertible securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r7", "r21", "r41", "r99", "r222" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r521" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r71", "r495", "r595" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "BIOF_AMGEnergyGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "AMGEnergyGroupMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "AMG Energy Group [Member]", "documentation": "AMG Energy Group [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://bluebiofuels.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF PROPERTY AND EQUIPMENT", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r30", "r32", "r50", "r51", "r183", "r472" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://bluebiofuels.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r24", "r122", "r477" ] }, "BIOF_IssuanceDateFebruaryTenTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateFebruaryTenTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 2/10/23 [Member]", "documentation": "Issuance Date February Ten Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r12" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r85", "r140" ] }, "BIOF_IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateFebruaryFourteenTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 2/14/23 [Member]", "documentation": "Issuance Date February Fourteen Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r524" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Profit (Loss) per Common Share:", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r27", "r28" ] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateAxis", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "BIOF_IssuanceDateMarchOneTwoThousandTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "IssuanceDateMarchOneTwoThousandTwentyThreeMember", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Issuance Date 3/1/23 [Member]", "documentation": "Issuance Date March One Two Thousand Twenty Three [Member]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r93", "r206", "r207", "r217", "r218", "r219", "r223", "r224", "r225", "r226", "r227", "r485", "r486", "r487", "r488", "r489" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r509" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://bluebiofuels.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patent Capitalization", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r36", "r358", "r359", "r360", "r362", "r480" ] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardDateDomain", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": [ "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://bluebiofuels.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r353", "r355" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails": { "parentTag": "us-gaap_NotesPayable", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://bluebiofuels.com/role/ScheduleOfNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Short Term Convertible Note \u2013 Related Party, including interest", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r16" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r509" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r13" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r517" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "BIOF_ChristopherJemapeteMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "ChristopherJemapeteMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Christopher Jemapete [Member]", "documentation": "Christopher Jemapete [Member]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r509" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "verboseLabel": "Preferred stock, shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r69", "r234" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r526" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "BIOF_InducementSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "InducementSharesMember", "presentation": [ "http://bluebiofuels.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Inducement Shares [Member]", "documentation": "Inducement Shares [Member]" } } }, "auth_ref": [] }, "BIOF_VertimassTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://bluebiofuels.com/20230930", "localname": "VertimassTechnologyMember", "presentation": [ "http://bluebiofuels.com/role/OrganizationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vertimass Technology [Member]", "documentation": "Vertimass Technology [Member]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expected life", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r288" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://bluebiofuels.com/role/ScheduleOfBlack-scholesOptionPricingModelsForWarrant-basedStockCompensationDetails" ], "lang": { "en-us": { "role": { "label": "BIOF common stock fair value", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r69", "r416" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bluebiofuels.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r514" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://bluebiofuels.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r69", "r416", "r434", "r596", "r597" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "presentation": [ "http://bluebiofuels.com/role/StatementsOfStockholdersEquityDeficitParenthetical", "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting of options previously issued under employee director plan", "verboseLabel": "Number of stock options vested, shares", "documentation": "Number of options vested." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "presentation": [ "http://bluebiofuels.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares unvested", "documentation": "Number of non-vested options outstanding." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(1),20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-40/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r477": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r482": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r483": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r484": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r485": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r486": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r487": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r488": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r489": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r490": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r491": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r492": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r494": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r495": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r496": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r497": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r507": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r508": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r509": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r511": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r513": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r514": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r515": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r516": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r517": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r518": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r519": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r520": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r521": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r522": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r524": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r525": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r526": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 55 0001493152-23-040402-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040402-xbrl.zip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�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

)#J'Z)AH! $*B"P , " =?5 !F;W)M >,3 M<2YH=&U02P4& H "@!E @ )_ ! end